Introduction {#s1}
============

The endoplasmic reticulum (ER) is a key cellular organelle coordinating a variety of essential processes such as protein synthesis and secretion, lipid biosynthesis, glucose metabolism and redox reactions. Additionally, ER is the main site of Ca^2+^ storage in the cell ([@bib15]; [@bib20]). Structurally, ER comprises a complex network of membranes spread throughout the cytoplasm, which establishes physical and functional contacts with many other organelles including mitochondria, endosomes, lipid droplets and the plasma membrane ([@bib29]; [@bib42]).

Given its critical role in the cell, the functionality of the ER is tightly monitored by proteins that can communicate stress signals to other proteins or compartments of the cell in order to restore ER function. The most well-known adaptive pathway in the ER is the unfolded protein response (UPR), which has the general goal of restoring ER function by enhancing ER folding capacity, decreasing protein translation and increasing protein degradation ([@bib15]; [@bib18]; [@bib20]; [@bib54]). Over the past decade it has been widely documented that chronic stress imposed by excess nutrients and energy leads to ER dysfunction and UPR activation in a variety of metabolic tissues in both mouse models and obese humans, which is associated with cellular stress, inflammation, and metabolic dysfunction ([@bib6]; [@bib16]; [@bib20]; [@bib33]; [@bib37]; [@bib47]; [@bib54]). Alleviation of ER stress by chemical or molecular chaperones dramatically improves metabolic control and insulin sensitivity and reduces inflammation in mouse models of obesity ([@bib14]; [@bib23]; [@bib36]; [@bib38]) as well as in humans ([@bib25]; [@bib59]).

More recently, it has become clear that Ca^2+^ storage in the ER is compromised in the setting of obesity and other metabolic diseases ([@bib3]; [@bib41]). Ca^2+^ in the ER is essential for chaperone-mediated protein folding and secretion, as well as for the function of metabolic enzymes. Ca^2+^ concentration in the ER is tightly regulated by coordinated action between SERCA, which pumps Ca^2+^ from the cytosol into the ER lumen, and the IP~3~ receptor (IP3R) or Ryanodine receptor, which release Ca^2+^ from the ER into the cytosol ([@bib7]). In obesity, hepatic SERCA activity is compromised ([@bib12]; [@bib32]; [@bib46]) while the activity of the IP3R1 Ca^2+^ channel is increased ([@bib2]; [@bib10]; [@bib53]). These alterations result in decreased ER Ca^2+^ content, loss of folding capacity, ER stress, inflammation, impaired insulin action and abnormal glucose metabolism ([@bib3]). Additionally, in this setting a 'leaky' ER contributes to both higher cytosolic Ca^2+^ and mitochondrial Ca^2+^ uptake, which has important implications for cytosolic Ca^2+^ signaling and mitochondrial dysfunction seen in metabolic diseases ([@bib2]; [@bib10]; [@bib40]; [@bib53]; [@bib59]). Accordingly, strategies to restore hepatic ER Ca^2+^ levels, such as overexpression of SERCA or suppression of IP3R, improve ER function and promote metabolic homeostasis in mouse models of obesity ([@bib2]; [@bib10]; [@bib12]; [@bib53]). In a similar fashion, administration of compounds that increase ER Ca^2+^ content and improve ER function, e.g. SERCA agonists ([@bib24]), IP3R antagonists ([@bib39]), or azoromide ([@bib14]), improves metabolic health in obese mice.

In addition to SERCA and IP3Rs, Ca^2+^ homeostasis in the ER is sensed and regulated by a third major adaptive/homeostatic system orchestrated by the STIM-Orai complex. STIM proteins (STIM1 and STIM2) are found in the ER and sense luminal Ca^2+^ through N-terminal Ca^2+^ binding EF hand domain. In the resting state, STIM proteins are bound to Ca^2+^ and spread evenly throughout the ER membrane. Upon ER Ca^2+^ release, STIM forms oligomers (seen in confocal microscopy as puncta), which translocate to junctions between ER and plasma membrane (PM), where they couple with the PM channel protein Orai1. This coupling results in the import of Ca^2+^ from the extracellular compartment to the cytosol, providing spatial Ca^2+^ signals that then influence cellular signaling and promote Ca^2+^ replenishment into the ER lumen through SERCA, in the process known as store operated Ca^2+^ entry or SOCE ([@bib11]; [@bib45]; [@bib49]; [@bib58]).

Given that obesity leads to impaired ER Ca^2+^ handling and this is a key mechanism associated with ER dysfunction in the obese condition, we examined whether alterations in SOCE system exist and contribute to the inability of ER to restore and or maintain Ca^2+^ levels. Here we show that STIM1 is modified and SOCE is defective in hepatocytes from obese mice due to the inability of STIM1 to translocate and couple with Orai1 at the PM. Hepatocytes lacking STIM1 displayed stress, increased glucose production and insulin resistance, whereas over-expression of STIM1 in the liver of obese mice significantly improved glucose intolerance. These findings support a critical role for STIM1-mediated SOCE in the maintenance of healthy Ca^2+^ balance in the ER, insulin action, and systemic glucose metabolism.

Results {#s2}
=======

In order to determine the impact of obesity on SOCE in the liver, we isolated primary hepatocytes from lean wild-type (WT) and genetically obese (*Lep^ob/ob^*) mice and measured Ca^2+^ influx through STIM/Orai1 using the ratiometric calcium dye, Fura-2AM ([@bib43]). First, the cells were incubated in Ca^2+^-free medium, and ER Ca^2+^ store depletion was induced by the addition of the SERCA inhibitor thapsigargin (Tg). In agreement with earlier reports ([@bib2]) the initial rise in cytosolic Ca^2+^ induced by Tg, which reflects the ER Ca^2+^ content, was significantly lower in hepatocytes isolated from obese animals compared with WT cells ([Figure 1A](#fig1){ref-type="fig"}). Next, we induced SOCE through STIM/Orai1 by substituting the Ca^2+^-free media with a media containing 2 mM Ca^2+^. As depicted in [Figure 1A](#fig1){ref-type="fig"}, the Ca^2+^ entry in primary hepatocytes from obese mice was markedly reduced relative to control cells. To further confirm that the observed Ca^2+^ entry was mediated by SOCE, we added the SOCE inhibitor 2-apb, which completely blocked Ca^2+^ influx in both genotypes ([Figure 1A](#fig1){ref-type="fig"}, dotted lines). This finding is consistent with a report of impaired SOCE in the steatotic hepatocytes from Zucker rats ([@bib57]).

![Obesity leads to decreased SOCE and impaired STIM1 translocation in primary hepatocytes.\
(**A**) Left panel: representative Fura-2AM based cytosolic Ca^2+^ measurements in primary hepatocytes isolated from wild type (WT) and leptin-deficient (*Lep^ob/ob^*) obese mice. ER Ca^2+^ stores were depleted with 1 µM thapsgargin (Tg), a SERCA inhibitor. SOCE was evaluated by substituting the extracellular media (0 mM Ca^2+^) with media containing 2 mM Ca^2+^. Dashed lines show Ca^2+^ measurements in the presence of 50 µM 2-Aminoethoxydiphenyl borate (2-APB). Right panel: quantification of Tg-induced Ca^2+^ release (reflecting ER Ca^2+^ content) and SOCE based on the measurements shown in (**A**), n = 160 WT and n = 250 *Lep^ob/ob^* cells for Tg response and n = 234 WT and n = 303 *Lep^ob/ob^* cells for SOCE response. Data were pooled across six independent experiments. \*p\<0.0001 (**B**) Left panel: Immunoblot analysis of protein expression levels in total liver lysate from WT and *Lep^ob/ob^* mice, Right panel: quantification of the western blots n = 4, representative of 4--5 experiments. (**C and D**) Confocal images of immunofluorescence staining for endogenous STIM1 in primary hepatocytes from WT and *Lep^ob/ob^* animals, treated with DMSO (vehicle, NT) or 1 µM Tg for 10 and 30 min. NT refers to 'not Tg treated' (**E**) Quantification of STIM1 puncta/cluster number in the bottom and middle cross-section of non-treated (DMSO) hepatocytes from WT and *Lep^ob/ob^* animals.n = 5--6 fields (WT) and 4--5 fields (*Lep^ob/ob^*), representative of 4 independent experiments, \*p=0.02 ^\#^p=0.003 (**F**) Quantification of pixel intensity in a set area (125 × 125 pixels) of the middle section of the cells from WT and *Lep^ob/ob^* animals, treated with 1 µM Tg or vehicle (quantification methods depicted in [Figure 1---figure supplement 1 F](#fig1s1){ref-type="fig"}), n = 4--9 cells, representative of 4 independent experiments, \*p=0.02 ^\#^p=0.008 (**G**) Representative profile plots of STIM1 levels (pixel intensities) in a defined area (box) across cells treated with DMSO or 1 µM Tg for 10 or 30 min. Left: cells from WT animals, right: cells from *Lep^ob/ob^* animals. (**H**) Quantification of STIM1 translocation by calculating the ratio between the mean STIM1 pixel intensity at a selected area of the edge of the cell relative to the same measurement performed in the cytosolic area near the edge of the cell, n = 3--4 ratios per cell, quantified in 2--8 cells for each condition \*p\<0.0001 \*\*p=0.009 (**I and J**) Representative TIRF images of STIM1 and Na^+^K^+^-ATPase (PM marker) in cells from WT (**I**) and *Lep^ob/ob^* mice (**J**) treated with 1 µM Tg or vehicle for 10 min. NT refers to "not Tg treated. For all graphs, error bars denote s.e.m. Scale: 10 µm.\
10.7554/eLife.29968.004Figure 1---source data 1.Source data for [Figure 1](#fig1){ref-type="fig"}.](elife-29968-fig1){#fig1}

As we observed impaired SOCE in hepatocytes from obese animals we next evaluated whether the expression levels of the main SOCE components were altered in obesity. As shown in [Figure 1---figure supplement 1A](#fig1s1){ref-type="fig"}, we did not detect differences in expression of Orai1 in the livers of mice with genetic or high-fat diet (HFD)-induced obesity. Despite a modest increase in the mRNA levels of stim1 and stim2, protein levels of STIM1, STIM2 and Orai1 remained unchanged in the livers of mice with both genetic and diet induced obesity ([Figure 1B](#fig1){ref-type="fig"} and [Figure 1---figure supplement 1B](#fig1s1){ref-type="fig"}). However, phospho-JNK (pJNK), a marker of inflammatory stress ([@bib19]) and phospho-Calmodulin kinase (pCaMKII), a marker of elevated cytosolic Ca^2+^ ([@bib39]), were increased in the livers of obese animals ([Figure 1B](#fig1){ref-type="fig"} and [Figure 1---figure supplement 1B](#fig1s1){ref-type="fig"}). Thus decreased Ca^2+^ import through SOCE in hepatocytes derived from obese mice appears to be independent of the expression levels of critical SOCE components.

We therefore asked whether the decreased Ca^2+^ import through SOCE in hepatocytes from obese mice was a result of a functional alteration in STIM1 translocation in the ER membrane. To evaluate the activity of STIM1 proteins in obesity, we first validated antibodies for endogenous immunostaining ([Figure 1](#fig1){ref-type="fig"}; [Figure 1---figure supplement 1C](#fig1s1){ref-type="fig"}). Next, we isolated primary hepatocytes from lean and obese mice, induced Ca^2+^ store depletion with Tg and determined STIM1 localization by immunostaining. As shown in [Figure 1C and D](#fig1){ref-type="fig"} and [Figure 1---figure supplement 1D](#fig1s1){ref-type="fig"}, while STIM1 was evenly distributed in the ER membrane of resting cells, Tg treatment led to a dramatic translocation to areas of the ER membrane in close proximity with the PM. This effect was observed within 5--10 min of Tg treatment and persisted for 30 min. However, in cells from obese (*Lep^ob/ob^*) mice, STIM1 distribution at baseline was punctate throughout the entire ER ([Figure 1D](#fig1){ref-type="fig"} and quantified in [Figure 1E](#fig1){ref-type="fig"}), and its translocation to areas of ER/PM junction in response to Tg was dramatically impaired. As shown in [Figure 1F](#fig1){ref-type="fig"} and [Figure 1---figure supplement 1E](#fig1s1){ref-type="fig"}, in WT cells, Tg treatment increased the number of high-intensity pixels, indicating the formation of the punctate structures, which represent oligomerization of STIM proteins. In contrast, hepatocytes derived from obese mice displayed higher intensity pixel counts at baseline with no further increase following Tg treatment. Defective STIM1 translocation in hepatocytes from obese animals is also illustrated in the line graphs showing the representative intensity profile of individual cells before and after Tg treatment ([Figure 1G](#fig1){ref-type="fig"} and also see [Figure 1---figure supplement 1F](#fig1s1){ref-type="fig"} for image analysis details). In WT cells, Tg treatment increased the signal intensity at the edge of the cell and decreased it in the cytosol, quantified as the STIM1 ratio between these compartments ([Figure 1H](#fig1){ref-type="fig"}). In hepatocytes from obese mice, the average signal intensity at baseline was higher than in WT cells, and did not change significantly in response to Tg ([Figure 1H](#fig1){ref-type="fig"}), indicating that STIM1 translocation is markedly defective in these cells.

To examine STIM1 translocation after Tg stimulation in more detail and using an alternative analytical tool, we performed total internal reflection fluorescence (TIRF) microscopy, in which fluorophores in the vicinity of the cell surface are selectively excited. As shown in [Figure 1I](#fig1){ref-type="fig"}, in WT cells Tg treatment induced STIM1 puncta formation and accumulation in areas close to the PM. This response was diminished in cells derived from obese animals ([Figure 1J](#fig1){ref-type="fig"}). In these experiments, Na^+^K^+^ ATPase was used as a constitutive marker of PM and its staining pattern did not change in the presence of Tg.

We also evaluated the time course of the defect in STIM1 trafficking during the development of obesity in mice. As shown in [Figure 1---figure supplement 2A](#fig1s2){ref-type="fig"} and [Figure 1---figure supplement 2B](#fig1s2){ref-type="fig"}, after 3 and 5 weeks of HFD, STIM1 showed some degree of translocation towards the plasma membrane in resting cells, indicating that short term HFD exposure is sufficient to trigger ER Ca^2+^ release, the driving force for STIM1 translocation. Additionally, at 3 weeks HFD, STIM1 translocation stimulated by Tg was not significantly impaired compared with cells derived from chow fed animals. However, the defect in STIM1 translocation induced by Tg was apparent in cells isolated from mice fed a HFD for 5 weeks and was more pronounced after 7 and 11 weeks of HFD ([Figure 1---figure supplement 2A](#fig1s2){ref-type="fig"} and [Figure 1---figure supplement 2B](#fig1s2){ref-type="fig"}). These data support that defective STIM1 translocation may be a common feature of obesity in independent experimental models (*Lep^ob/ob^* and HFD) and that this phenotype occurs independent of blood glucose levels and prior to the emergence of marked hyper-insulinemia and insulin resistance found in obesity ([Figure 1---figure supplement 2C](#fig1s2){ref-type="fig"}).

Next, we examined the activation and translocation of STIM2 in cells from lean (WT) and obese (*Lep^ob/ob^*) mice. The role of STIM2 in the regulation of SOCE has been explored only recently, and its activation seems to result from smaller fluctuations in Ca^2+^ due to its lower affinity for the ion, while STIM1 is activated when the extent of ER depletion increases ([@bib5]; [@bib34]; [@bib45]). In hepatocytes, STIM2 is expressed at a lower level than STIM1 ([@bib30]; [@bib56]), however it was detectable both by staining and by western blot analysis. We did not observe aberrant STIM2 puncta formation in cells from *Lep^ob/ob^* mice but a tendency for translocation at baseline. Upon Tg-induced store depletion, we observed a marked STIM2 translocation to areas close to the PM in both WT cells and *Lep^ob/ob^* cells, however the degree of translocation in *Lep^ob/ob^* cells was less pronounced than in WT cells ([Figure 1---figure supplement 3A](#fig1s3){ref-type="fig"}). Thus, the obesity-related defect in STIM2 translocation was present but less dramatic than that observed for STIM1. Overall, these findings suggest that defective SOCE in primary hepatocytes from obese mice is predominantly related to aberrant STIM1 puncta formation and inefficient STIM1 re-localization from the bulk ER membrane to ER/PM junction areas after ER Ca2+ store depletion.

In order to gain insight into mechanisms underlying this phenomenon, we considered the possibility that altered STIM1 post-translational modification could be involved in its defective translocation capacity in the context of obesity. Two known post-translational modifications of STIM1 which influence its trafficking are phosphorylation and O-GlcNAcylation ([@bib44]; [@bib62]). Phosphorylation of STIM1 at Ser621 and Ser575 regulate its interaction with the microtubule plus-end-tracking protein EB1, enabling STIM1 to move in the ER membrane ([@bib44]). Therefore, we asked whether a reduction in STIM1 phosphorylation at these sites may explain its defective trafficking in obesity. Surprisingly however, we found that phosphorylation of STIM1 at Ser621 and Ser575 was actually increased in liver lysates from obese mice ([Figure 2A](#fig2){ref-type="fig"}). This indicates that lack of phosphorylation at these residues does not underlie the defective translocation of STIM1, and suggests that hepatic STIM1 may be released from EB1 in the basal state, potentially as a response to the decreased ER Ca^2+^ level observed in hepatocytes from obese mice.

![Post-translational modification of STIM1 by phosphorylation and O-GlcNAcylation in obesity.\
(**A**) Immunoblot analysis of the phosphorylation level of STIM1 at Ser575 and Ser621 and of ERK phosphorylation in total liver lysates from WT and *Lep^ob/ob^* animals (**B**) Immunoblot analysis of O-GlcNAcylation of total lysates extracted from primary hepatocytes derived from WT and *Lep^ob/ob^* animals in the presence or absence of overnight treatment with 10 µM of PugNac, an inhibitor of O-GlcNAcase. (**C**) Immunoprecipitation of O-GlcNAcylated proteins derived from WT and *Lep^ob/ob^* hepatocytes followed by immunoblotting for STIM1. Cells from STIM1-deficient mice (STIM1Δ^Liver^) were used as a negative control. (**D**) Total lysates from WT or *Lep^ob/ob^* hepatocytes treated or not with 10 µM of PugNac overnight were incubated with biotinylated, succinylated WGA and precipitated with streptavidin-conjugated beads. The recovered proteins were used for immunoblotting for STIM1. An aliquot of each precipitate was run in a gel and silver stained. (**E**) Immunoprecipitation of STIM1 in total lysates from primary hepatocytes derived from WT and *Lep^ob/ob^* animals followed by immunoblotting for OGT. Input for OGT and STIM1 in the total lysates prior to immunoprecipitation is shown (**F**) Immunoprecipitation of STIM1-Flag from total lysates stably expressing STIM-Flag in the presence or absence of OGT followed by immunoblotting for O-GlcNac and OGT. (**G**) Confocal images of endogenous immunofluorescent staining of STIM1 in Hepa1-6 cells transfected with OGT, treated with DMSO or 1 µM Tg stimulation. Non-transfected cells present in the same dish were used as controls for quantification. OGT expressing cells were identified by the presence of RFP expression. NT refers to 'not Tg treated' (**H**) Number of STIM1 puncta quantified per cell, n = 7--14 cells per group, representative of 3 independent experiments, \*p=0.0003 ^\#^p=0.03. (**I**) Quantification of STIM1 translocation by calculating the ratio between STIM1 protein signal at the edge of cell relative to the cytosol close by. For OGT n = 60--64 areas and for OGT +n = 22--30 areas per group, representative of 3 independent experiments,\*p\<0.0001 \#p=0.004 (**J**) Left panel: representative Fura-2AM based cytosolic Ca^2+^ measurements in Hepa1-6 cells overexpressing pcDNA control or OGT. Right panel: quantification of Ca^2+^ influx through SOCE. n = 51 (pcDNAt +DMSO) n = 61 (OGT +PugNAc) \*p=0.0007. (**K and L**) Immunoblot analysis and densitometric quantification of OGT and OglcNAc expression in primary hepatocytes from *Lep^ob/ob^* animals infected with adenovirus expressing scrambled shRNA (shSCR) and shRNA against OGT (shOGT) for 48 hr. (**M**) Confocal images of immunofluorescence staining for endogenous STIM1 in primary hepatocytes from *Lep^ob/ob^* animals expressing scrambled shRNA (shSCR) and shRNA against OGT (shOGT) for 48 hr. NT refers to 'not Tg treated' (**N**) Quantification of STIM1 translocation by calculating the ratio between the mean STIM1 pixel intensity at a selected area of the edge of the cell relative to the same measurement performed in the cytosolic area near the edge of the cell, n = 3 ratios per cell, 5 cells per field in four fields per condition,\*p=0.04 \# p\<0.001.For all graphs, error bars represent s.e.m. Scale: 10 µm.](elife-29968-fig2){#fig2}

STIM1 can also be modified by O-linked N-acetyl glucosamine (O-GlcNAc), a post-translational modification of serine or threonine amino acids. Previous work has shown that STIM1 O-GlcNAcylation impairs the ability of the protein to move in the ER membrane and to form punctate structures ([@bib62]). Additionally, conditions of nutrient and substrate excess, including obesity, lead to increase in cellular O-GlcNAcylation levels ([@bib52]; [@bib61]; [@bib8]; [@bib60]). These studies indicate the possibility that metabolic stress may interfere with SOCE via O-GlcNAcylation of STIM1, which disrupts its proper trafficking. To test this hypothesis, we first examined global O-GlcNAcylation in primary hepatocytes from WT and obese mice. As shown in [Figure 2B](#fig2){ref-type="fig"}, and in agreement with previous observations ([@bib4]), global O-GlcNAcylation was higher in hepatocytes derived from obese animals compared with their controls. This effect was amplified by treatment with PugNac, a specific inhibitor of O-GlycNAcase (OGA), the enzyme that catalyzes removal of OglcNAc sugars from proteins. Next, we performed immunoprecipitation of O-GlcNAc-modified proteins using an OglcNAc-specific antibody from hepatocyte lysates. We found that STIM1 was present among the OglcNAcylated proteins and it was more abundant in cells from obese mice ([Figure 2C](#fig2){ref-type="fig"}). As a complementary approach, we utilized biotinylated-succinylated wheat germ agglutinin (succinylated-WGA), a lectin that preferentially binds *N*-acetylglucosamine versus other sugars ([@bib4]; [@bib22]). Following precipitation with streptavidin-conjugated magnetic beads, STIM1 was detected in the pool of proteins modified by O-GlcNac at higher levels in samples derived from obese animals relative to WT controls ([Figure 2D](#fig2){ref-type="fig"}). Additionally, as shown in [Figure 2E](#fig2){ref-type="fig"}, OGT precipitates with STIM1 in hepatocytes derived from obese animals, indicating that OGT and STIM1 exist in a complex in obesity, consistent with higher levels of O-GlcNac-modified STIM1 in this condition. To explore whether STIM1 is also modulated by OglcNAcylation in the HFD context and study the time course of this modification, we isolated hepatocytes from animals fed a HFD for 3, 5 and 11 wks and pull down STIM1 using succinylated-WGA. As shown in [Figure 2---figure supplement 1A](#fig2s1){ref-type="fig"}, STIM1 was progressively modified by O-GlcNac in this context starting at 3 weeks on HFD.

In order to test if O-GlcNAc modification may alter STIM1 function in hepatocytes, we first overexpressed OGT in Hepa1-6 cells. As expected, overexpression of OGT strongly increased global protein modification with O-GlcNac ([Figure 2---figure supplement 1B](#fig2s1){ref-type="fig"}). We then co-expressed OGT and STIM1 tagged with a Flag peptide ([Figure 2---figure supplement 1C](#fig2s1){ref-type="fig"}) to determine whether STIM1 can be directly O-GlcNacylated by OGT in this system. Immunoprecipitation of STIM1-Flag with a Flag specific antibody demonstrated its enhanced O-GlcNAc modification in OGT overexpressing cells ([Figure 2F](#fig2){ref-type="fig"}). Additionally, STIM1 is able to directly bind to OGT in this cell model ([Figure 2F](#fig2){ref-type="fig"}), similar to what we observed in hepatocytes derived from obese animals ([Figure 2E](#fig2){ref-type="fig"}). Having established this cellular system with enhanced STIM1 O-GlcNacylation, we then assessed its translocation in cells transfected with OGT labeled with RFP, using un-transfected cells in the same culture plate as internal controls for quantification ([Figure 2G](#fig2){ref-type="fig"}). These experiments showed that STIM1 puncta formation and translocation following Tg treatment was markedly impaired in cells overexpressing OGT compared with control cells ([Figure 2G,H and I](#fig2){ref-type="fig"}). Additionally, overexpression of OGT led to a significant impairment in SOCE compared with the controls ([Figure 2J](#fig2){ref-type="fig"}), with no significant differences in the response to Tg (data not shown).

Next, to determine whether inhibition of the O-GlcNac modification could rescue STIM1 translocation defect in *Lep^ob/ob^* cells, we used adenoviral gene delivery to express an shRNA targeting OGT to down-regulate OGT and thus the O-GlcNacylation capacity of the cell. As can be seen in [Figure 2K and L](#fig2){ref-type="fig"}, the expression of OGT shRNA lead to a 60% decrease in its expression and activity. As shown in [Figure 2M and N](#fig2){ref-type="fig"}, down-regulation of OGT resulted in increased STIM1 translocation capacity compared with cells expressing a scrambled shRNA. Taken together these data indicate that increased modification of STIM1 by OglcNAc could, at least in part, underlie defective STIM1 translocation and reduced hepatic SOCE in the context of obesity.

We then started to investigate the impact of defective STIM1-mediated SOCE on ER homeostasis, cellular stress responses and metabolic regulation in STIM1-deficient hepatocyte cell models. These included primary hepatocytes derived from mice with genetic STIM1 deficiency specifically in the liver (stim1*^fl/fl^ Alb;Cre*, identified here as stim1Δ^LIVER^) and Hepa1-6 cells stably expressing shRNAs targeting stim1 ([Figure 3---figure supplement 1A](#fig3s1){ref-type="fig"}) or stim2 ([Figure 3---figure supplement 1B](#fig3s1){ref-type="fig"}) (identified here as shSTIM1 and shSTIM2 respectively). Primary hepatocytes derived from stim1Δ^LIVER^ mice displayed lower ER Ca^2+^ content and absence of Tg-triggered SOCE compared to controls (stim1*^fl/fl^*) ([Figure 3A](#fig3){ref-type="fig"}). Similarly, Hepa 1--6 cells in which STIM1 expression was down regulated showed markedly blunted SOCE ([Figure 3---figure supplement 1C](#fig3s1){ref-type="fig"}). Imbalances in ER Ca^2+^ content trigger cellular stress responses through various pathways ([@bib3]; [@bib13]; [@bib41]). In order to examine these responses in our cellular models of STIM deficiency, we measured phosphorylation of JNK as a benchmark measure of cellular stress and inflammatory activation, and phosphorylation of eIF2α as a marker of UPR activation. As shown in [Figure 3B](#fig3){ref-type="fig"}, in stim1*^fl/fl^* control cells, treatment with Tg induced phosphorylation of JNK and eIF2α at 30 min followed by a decrease in phosphorylation levels back to baseline after 90 min. However, in STIM1-deficient cells, the phosphorylation of JNK and eIF2α was enhanced at baseline and these cells displayed a stronger and more persistent response to Tg, with stress markers only returning to basal levels at 120 min. A similar profile was observed in Hepa1-6 cells with shRNA-mediated suppression of STIM1 ([Figure 3---figure supplement 1D](#fig3s1){ref-type="fig"}). Interestingly, suppression of STIM2 alone did not alter the cellular response to Tg ([Figure 3---figure supplement 1E](#fig3s1){ref-type="fig"}). Altogether, these data demonstrate that absence of core components of SOCE leads to elevated and prolonged stress responses in hepatocytes.

![STIM1 deficiency leads to increased cellular stress, insulin resistance and lipid droplet accumulation.\
(**A**) Left panel: representative Fura-2AM-based cytosolic Ca^2+^ measurements in primary hepatocytes isolated from stim1*^fl/fl^* and stim1Δ^LIVER^ mice. Right panel: quantification of Tg-induced Ca^2+^ release (reflecting ER Ca^2+^ content) and SOCE. Error bars denote s.e.m. n = 98 WT and n = 116 stim1Δ^LIVER^ for Tg response and n = 69 stim1*^fl/fl^* and n = 101 stim1Δ^LIVER^ for SOCE. Cells were pooled across four independent experiments. \*p\<0.0001 (**B**) Immunoblot analysis and quantification of the expression levels of stress markers in primary hepatocytes isolated from stim1*^fl/fl^* and stim1Δ^LIVER^ mice. n = 6 samples in each group, pooled across three independent experiments for pJNK and n = 2 for peIF2α, \*p=0.0138 ^\#^p\<0.0001. (**C**) Immunoblot analysis and quantification of insulin signaling before and after 3 nM insulin (Ins) treatment for the indicated time points in primary hepatocytes isolated from stim1*^fl/fl^* and stim1Δ^LIVER^ mice. n = 4--5 samples in each group, pooled across two independent experiments for pIR. \*p=0.011 and pAKT \*p=0.03 and ^\#^p=0.0088 (**D**) Primary hepatocytes isolated from stim1*^fl/fl^* and stim1Δ^LIVER^ animals treated or not with a mixture containing 1 mM Oleic Acid and 40 µM palmitic acid for 16 hr. Lipid droplets were stained in green with BODIPY and the nucleus in blue with DAPI. Scale: 10 µm. (**E**) Glucose output derived from primary hepatocytes isolated from stim1*^fl/fl^* and stim1Δ^LIVER^ mice kept on a HFD, n = 4 stim1*^fl/fl^* and n = 4 stim1Δ^LIVER^\*p=0.046 (**F**) Schematic representation of the protocol for adenovirus-mediated transient hepatocyte knockdown of STIM1 (**G**) Immunoblot analysis of the indicated proteins in total liver lysates derived from stim1*^+/+^* n = 4 and n = 4 stim1*^fl/fl^* mice, both groups expressing liver-specific Cre recombinase (ad *Alb;Cre*) adenovirus. (**H and I**) 16 hr fasting blood glucose levels (**H**) and insulin (**I**) in animals of the indicated genotypes. \*p=0.0094 stim1*^+/+^* versus stim1*^fl/fl^* and ^\#^p\<0.0001 stim1*^fl/+^* versus stim1*^fl/fl^* (**J**) Glucose tolerance test (GTT) in stim1*^+/+^*, stim1*^fl/+^* and stim1*^fl/fl^* animals expressing adenoviral *Alb;Cre* recombinase \*p\<0.04; Right panel: quantification of area under the curve from GTT. n = 5 stim1*^+/+^*, n = 6 stim1*^fl/+^*, n = 8 stim1*^fl/fl^* animals, \*p=0.03 stim1*^+/+^*, versus stim1*^fl/fl^* and ^\#^p=0.01 stim1*^fl/+^* versus stim1*^fl/fl^*, representative of 2 independent experiments. For all graphs, error bars denote s.e.m.\
10.7554/eLife.29968.014Figure 3---source data 1.Source data for [Figure 3](#fig3){ref-type="fig"}.](elife-29968-fig3){#fig3}

Increased cellular stress and inflammation are associated with impaired insulin action and defective glucose and lipid metabolism ([@bib13]; [@bib19]; [@bib21]). Accordingly, we found that primary hepatocytes derived from stim1Δ^LIVER^ mice displayed impaired phosphorylation of IRβ and AKT in response to insulin relative to cells from stim1*^fl/fl^* littermates ([Figure 3C](#fig3){ref-type="fig"}). Likewise, gene silencing of stim1 in Hepa1-6 cells resulted in decreased insulin signaling ([Figure 3---figure supplement 1F](#fig3s1){ref-type="fig"}). Additionally, primary hepatocytes isolated from stim1Δ^LIVER^ mice maintained on HFD showed higher levels of glucose production stimulated by the gluconeogenesis substrates glycerol, pyruvate and glutamine compared to stim1*^fl/fl^* derived hepatocytes ([Figure 3E](#fig3){ref-type="fig"}). In agreement with our finding that STIM2 suppression does not amplify stress responses, we found that STIM2-deficient cells retained normal insulin responsiveness ([Figure 3---figure supplement 1G](#fig3s1){ref-type="fig"}).

Recently, it has been shown that SOCE may regulate lipid metabolism ([@bib31]; [@bib57]) and animals with inducible STIM1/2 whole body deficiency exhibit increased lipid accumulation in multiple tissues such as skeletal muscle, heart and liver, as a consequence of impaired lipolysis and fatty acid oxidation ([@bib31]). We observed that primary hepatocytes isolated from stim1Δ^LIVER^ mice showed modestly increased accumulation of lipid droplets at baseline and after incubation with 1 mM oleic acid and 40 µM of palmitic acid ([Figure 3D](#fig3){ref-type="fig"}). These results suggest that in addition to higher stress levels, insulin resistance and increased glucose production, SOCE deficiency may result in abnormal lipid metabolism.

We next assessed the systemic metabolic impact of STIM1 deficiency in hepatocytes in vivo in the stim1Δ^LIVER^ mice described above. As shown in [Figure 3---figure supplement 2A](#fig3s2){ref-type="fig"}, liver lysates from stim1Δ^LIVER^ mice displayed marked reduction in STIM1 and a mild increase in STIM2 protein. On a chow diet, stim1Δ^LIVER^ mice gained weight equivalently to stim1*^fl/fl^* mice ([Figure 3---figure supplement 2B](#fig3s2){ref-type="fig"}) and did not exhibit alterations in glucose tolerance and triglyceride content (Tg) (data not shown). In the HFD-fed mice, the weight gain was similar between genotypes ([Figure 3---figure supplement 2B](#fig3s2){ref-type="fig"}). Interestingly, at 6 weeks on a HFD, we observed a mild, but significant, glucose intolerance in the stim1Δ^LIVER^ animals compared with the stim1*^fl/fl^* controls ([Figure 3---figure supplement 2C](#fig3s2){ref-type="fig"}). Additionally, at this time point, insulin sensitivity was impaired ([Figure 3---figure supplement 2D](#fig3s2){ref-type="fig"}). No significant differences were observed in Tg content between the two genotypes, although a tendency to higher Tg levels was detected in stim1Δ^LIVER^ mice ([Figure 3---figure supplement 2E](#fig3s2){ref-type="fig"}). In long term HFD (20 weeks), the differences in glucose intolerance, insulin signaling and Tg content between stim1*^fl/fl^* and stim1Δ^LIVER^ groups were very mild and did not reach statistical significance ([Figure 3---figure supplement 2F,G and H](#fig3s2){ref-type="fig"}).

Interestingly, although we haven't observed overall changes in lipid accumulation in the liver specific STIM1 deficient animals, we have noticed that these animals showed higher content of microvesicular steatosis compared with controls where the majority of the lipid droplets are presented as large droplets ([Figure 3---figure supplement 2I](#fig3s2){ref-type="fig"}).

In light of the mild in vivo metabolic phenotype of constitutive hepatocyte-specific STIM1 deletion during development, we considered that STIM2 upregulation ([Figure 3---figure supplement 2](#fig3s2){ref-type="fig"}) or alternative systems could compensate for the lack of STIM1 all throughout the embryonic life. Therefore, we examined the effect of acute deletion of STIM1 in hepatocytes, using adenovirus mediated gene delivery to express albumin-Cre recombinase (*Alb;Cre*) in adult stim1^+/+^ and stim1^fl/fl^ mice. After weaning, littermate animals were subjected to HFD for 4 weeks (for a short-term stress induction) ([Figure 3F](#fig3){ref-type="fig"}). Adenoviral delivery of *Alb;Cre* recombinase resulted in \~60% deletion of hepatic STIM1 ([Figure 3G](#fig3){ref-type="fig"}). Importantly, there was no compensatory upregulation of STIM2 or Orai1 in this setting. Indeed, one week after adenovirus administration, the acute deletion of STIM1 resulted in significantly higher fasting glucose levels ([Figure 3H](#fig3){ref-type="fig"}) without any difference in insulin levels ([Figure 3I](#fig3){ref-type="fig"}) and body weight (data not shown). Interestingly, following STIM1 deletion, mice also exhibited significantly impaired glucose tolerance ([Figure 3J](#fig3){ref-type="fig"}). In summary, acute SOCE dysfunction in the liver results in amplified cellular stress and glucose intolerance in mice fed a HFD.

Based on these observations, and the marked SOCE defect associated with obesity we hypothesized that recovery of SOCE function in the livers of obese mice could improve metabolic homeostasis in obesity. To test this hypothesis, we used a hepatocyte-specific adenovirus system to exogenously express either GFP (control) or STIM1-YFP in the *Lep^ob/ob^* primary hepatocytes and mice ([Figure 4A](#fig4){ref-type="fig"}). The functionality of the STIM1-YFP fusion protein has been verified previously ([@bib26]) and confirmed by us ([Video 1](#video1){ref-type="video"}).

![Overexpression of STIM1 promotes STIM1 translocation to ER/PM junctions and improves SOCE in primary hepatocytes from obese animals.\
(**A**) Immunoblot analysis of STIM1-YFP expression levels in total lysates from livers isolated from *Lep^ob/ob^* mice transduced with adenovirus (Ad) expressing GFP or STIM1-YFP. (**B--C**) Confocal images of immunofluorescence staining for endogenous STIM1 in primary hepatocytes from *Lep^ob/ob^* mice expressing adGFP (**B**) or adSTIM1-YFP (**C**) treated with DMSO (vehicle) and 1 µM Tg. NT refers to 'not Tg treated'. (**D**) Quantification of STIM1 translocation by calculating the ratio between the mean STIM1 pixel intensity at a selected area of the edge of the cell relative to the same measurement performed in the cytosol. n = 26 adGFP NT and Tg treated and n = 16 adSTIM1-YFP NT and n = 19 Tg treated \*p=0.0023, ^\#^p=0.0015. Scale: 10 µm. (**E**) Transmission Electron Micrographs of primary hepatocytes isolated from *Lep^ob/ob^* animals expressing STIM1-HRP, treated with DMSO or treated 1 µM Tg for 10 min. Scale: 500 nm. (**F**) Immunoblot analysis and densitometric quantification of OglcNac and STIM1 expression in primary hepatocytes from *Lep^ob/ob^* animals infected with AdGFP and AdSTIM1-YFP adenovirus for 24 hr. Quantification reflects the sum of the endogenous and exogenous STIM1 (**G**) Left: Representative Fura-2AM-based cytosolic Ca^2+^ measurements in primary hepatocytes isolated from *Lep^ob/ob^* animals expressing adGFP or adSTIM1-YFP. Right: Quantification of Tg-induced Ca^2+^ release (reflecting ER Ca^2+^ content) and SOCE measurements . n = 126 adGFP and n = 83 adSTIM1-YFP cells for Tg response and n = 127 adGFP and n = 62 adSTIM1-YFP cells for SOCE, representative of 5 independent experiments. \*p\<0.0001. For all graphs. error bars denote s.e.m.\
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###### STIM1-YFP translocation upon thapsigargin (Tg) treatment.

Primary Hepatocytes were infected with STIM1-YFP, treated with 1 uM Tg and YFP fluoresce was recorded over the period of time indicated in the movie.

10.7554/eLife.29968.022

Using this approach, we asked whether exogenous expression of STIM1-YFP would be sufficient to overcome the SOCE defects in primary hepatocytes from obese animals. As shown in [Figure 4B](#fig4){ref-type="fig"}, in control *Lep^ob/ob^* cells expressing GFP, STIM1 formed puncta at baseline and Tg-induced translocation of the protein was impaired, as we previously observed ([Figure 1D](#fig1){ref-type="fig"}). Delivery of STIM1-YFP lead to a significant increase in the protein level in liver cells. Interestingly, in non treated cells, we observed that some degree of the STIM1 protein was already localized in areas of close contact with the plasma membrane even prior to stimulation ([Figure 4C](#fig4){ref-type="fig"}). Additionally, exogenously expressed STIM1 was able to translocate towards the plasma membrane after Tg treatment ([Figure 4C and D](#fig4){ref-type="fig"}). To examine STIM1 translocation in *Lep^ob/ob^* hepatocytes with higher resolution, we also performed TEM in cells expressing exogenous STIM1 fused with HRP. STIM1-HRP-expressing cells were fixed and treated with diaminobenzidine (DAB) in the presence of H~2~O~2~. HRP catalyzes the polymerization and deposition of DAB, which recruits electron-dense osmium, providing contrast and revealing the localization of STIM1. As shown in [Figure 4E](#fig4){ref-type="fig"}, exogenous delivery of STIM1-HRP resulted in rescue of translocation in cells from obese animals in a manner similar to that observed in lean, wild type cells. Taken together, these data indicate that exogenously increasing the amount of STIM1 protein is sufficient to partially overcome the STIM1 translocation defect in cells from obese mice.

The ability of STIM1-YFP overexpression to overcome, at least in part, the translocation defect of endogenous STIM1 in *Lep^ob/ob^* cells suggests that at least some proportion of STIM1 in this setting may escape the O-GlycNac modification. To examine the degree of O-GlcNacylation of overexpressed STIM1-YFP in *Lep^ob/ob^* cells, we used an O-GlcNac specific antibody to immunoprecipitate all proteins modified by O-GlycNacylation in GFP or STIM1 YFP overexpressing cells and examined STIM1 protein by immunoblotting. As shown in [Figure 4F](#fig4){ref-type="fig"}, STIM1-YFP overexpression resulted in an \~20 fold increase in the expression of STIM1 protein. However, the amount of O-GlcNac modified STIM1 did not increase proportionally, indicating that in fact a significant amount of the overexpressed STIM1 escapes this post translation modification.

Additionally, it has been previously shown that overexpression of STIM1 in HeLa cells leads to morphological changes in the ER with an increased cortical ER ([@bib35]). In agreement with this finding, electron micrographs of primary hepatocytes derived from *Lep^ob/ob^* mice show that STIM1-YFP expression led to a remodeling of ER with abundant ER stacks apposed to the PM, although the degree of ER remodeling varied from cell to cell, likely due to variable STIM1 expression levels ([Figure 4---figure supplement 1A](#fig4s1){ref-type="fig"}). This result suggests that, in addition to having more STIM1 that translocates to PM, overexpression of STIM1-YFP also remodels the ER, favoring the proximity of STIM1 to Orai at the plasma membrane.

After verifying that overexpression of STIM1-YFP was able to rescue STIM1 translocation defects in obese cells, we examined whether this actually resulted in improved SOCE. As shown in [Figure 4G](#fig4){ref-type="fig"} overexpression of STIM1-YFP in *Lep^ob/ob^* cells resulted in increased ER Ca^2+^ and SOCE compared to control cells. Thus, overexpression of STIM1 was a successful intervention to overcome the STIM translocation and SOCE defects, resulting in improved ER calcium handling.

Next, we asked whether the effects of the overexpression of STIM1-YFP in *Lep^ob/ob^* primary hepatocytes would impact overall metabolism in vivo, and evaluated the effect of liver-specific STIM1 expression on systemic glucose metabolism in the *Lep^ob/ob^* mice following the protocol displayed in [Figure 5A](#fig5){ref-type="fig"}. Introduction of STIM1 by adenovirus gene delivery led to increased STIM1 protein levels in the liver. Interestingly, increased STIM1 expression was also accompanied by increased mRNA expression of Orai1 and with an increase in SERCA (Atp2a2) mRNA and protein levels ([Figure 5B and C](#fig5){ref-type="fig"}). This is in accordance with previous work showing that the modulation of expression STIM1 affects the expression of other Ca^2+^ channels or pumps, as SERCA, likely due to alterations in cytosolic Ca^2+^ levels ([@bib1]). Remarkably, liver-specific overexpression of STIM1 led to a significant improvement in glucose tolerance relative to control (adGFP) animals as evaluated by a glucose tolerance test ([Figure 5D](#fig5){ref-type="fig"}). Improved glucose tolerance resulting from overexpression of STIM1 was associated with enhanced in vivo insulin signaling evaluated by direct insulin injection into the livers that resulted in increased AKT phosphorylation ([Figure 5E](#fig5){ref-type="fig"}). Additionally, expression of genes involved in glycolysis were increased in livers overexpressing STIM1, accompanied by decreased levels of PCK1 (PEPCK), a rate limiting enzyme for gluconeogenesis ([Figure 5F and G](#fig5){ref-type="fig"}).

![Overexpression of STIM1 leads to improved insulin signaling, glucose tolerance and lipid accumulation in obese animals.\
(**A**) Schematic representation of the protocol for adenovirus mediated STIM1- YFP expression in *Lep^ob/ob^* mice (**B**) mRNA expression levels of indicated genes evaluated by qPCR, normalized to 18S, n = 9 for WT and n = 10 for STIM1-YFP pooled from two independent experiments, \*p=0.04 (**C**) Left panel: Immunoblot analysis of indicated proteins in liver total lysates from *Lep^ob/ob^* mice expressing GFP or STIM1-YFP. Right panel: quantifications of the blots. n = 3 adGFP and n = 4 adSTIM1-YFP, \*p=0.001 (**D**) Glucose tolerance tests in *Lep^ob/ob^* mice after adGFP (control) and adSTIM1-YFP expression with quantifications of area under the curve. n = 7 adGFP and n = 11 adSTIM1-YFP animals, representative of 3 independent experiments.\*p=0.022 (**E**) Markers of in vivo insulin signaling evaluated by immunoblot analysis of total liver lysates from animals injected with insulin (0.75 U/kg) through the portal vein. Tissues were collected 3 min after injection. Right panel: phospho-protein level quantification normalized to total protein levels. n = 3 for adGFP and n = 4 for adSTIM1-YFP, \*p=0.0003. (**F and G**) mRNA expression levels of indicated genes evaluated by qPCR, normalized to 18S, n = 9 for both WT and STIM1-YFP pooled from two independent experiments. \*p\<0.01 \# p\<0.04. (**H**) Liver triglyceride content in *Lep^ob/ob^* animals expressing adGFP (control) and adSTIM1-YFP pooled from three independent cohorts. n = 14 adGFP and 17 adSTIM1-YFP, \*p=0.042. For all graphs, error bars denote s.e.m.\
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Given the reported role of STIM1 in lipid metabolism, we also evaluated if overexpression of STIM1 impacted the excessive lipid accumulation in the livers of *Lep^ob/ob^* animals. As shown in [Figure 5H](#fig5){ref-type="fig"}, exogenous expression of STIM1 led to a reduction in total Tg content in the liver tissue of *Lep^ob/ob^* mice compared to controls expressing GFP. Accordingly, STIM1 overexpression led to increase mRNA expression of genes involved in fatty acid oxidation, such as CPT1, while no change was observed in genes involved in lipogenesis ([Figure 5---figure supplement 1A and B](#fig5s1){ref-type="fig"}). Based on these results we conclude that SOCE is critical for glucose and lipid metabolism and that increasing hepatic SOCE through overexpression of STIM1 is able to revert, at least in part, the deleterious impact of obesity on systemic glucose homeostasis.

Discussion {#s3}
==========

In the last several years, a growing number of studies have laid the foundation for the concept that disrupted intracellular Ca^2+^ homeostasis in metabolic tissues is a key component of ER dysfunction and metabolic deterioration ([@bib3]; [@bib41]). The abnormal Ca^2+^ handling in the ER of hepatocytes in this setting is multi-faceted, involving both impairment of SERCA activity ([@bib12]) as well as increased activity of IP3R ([@bib2]; [@bib10]; [@bib53]). This impacts not only Ca^2+^ levels in the ER and protein folding, but also mitochondrial oxidation and ROS production as well as the activation of cytosolic stress signaling pathways. Supporting the critical role of this biology, human genetic studies have shown that SNPs in SERCA ([@bib51]) and IP3R ([@bib48]) are associated with metabolic diseases such as obesity and diabetes. Here, our work reveals that another key mechanism supporting ER Ca^2+^ homeostasis, STIM-mediated SOCE, is also defective in obesity with important implications for the metabolic dysfunction in hepatocytes. Strikingly, we demonstrate that STIM1 gain-of-function improves cellular stress responses and glucose homeostasis in obese mice, underscoring the therapeutic potential of targeting Ca^2+^ homeostasis through STIM1 for metabolic disease treatment.

Our interest in this biology was heightened by our initial observation that in hepatocytes isolated from obese (*Lep^ob/ob^*) mice, STIM1 was present in an aberrant punctate pattern along the ER membrane. One possible explanation was that *Lep^ob/ob^* hepatocytes display increased SOCE even in baseline conditions in order to respond to low ER Ca^2+^ levels induced by dysfunction of SERCA and IP3R1. However, our detailed examination revealed that in cells of obese mice, STIM1 puncta were not localized in areas of close proximity of the PM, but rather were distributed all throughout the cell away from the PM. Additionally, when we depleted ER Ca^2+^ stores, STIM1 was not able to fully translocate to the PM, resulting in significantly reduced SOCE. Hence, metabolic stress impairs this critical component of ER Ca^2+^ homeostasis in obese liver tissue.

One question arising from these observations is the nature of the mechanism underlying STIM1 dysfunction in obesity. STIM activation and translocation is modulated by a complex array of factors that include post-translational modification of the protein itself, protein-protein interactions (for review [@bib28]), the interaction of STIM1 with lipids of the ER membrane and the ability of the ER itself to remodel and form ER/PM junctions ([@bib9]; [@bib28]; [@bib45]). Here we found that in hepatocytes derived from *Lep^ob/ob^* mice, STIM1 displays significantly increased levels of O-GlcNAcylation, a post-translation modification that causes impaired STIM1 trafficking and function ([@bib62]). Indeed, overexpression of OGT in hepatocytes was sufficient to induce abnormal STIM1 puncta formation and impaired activation of SOCE while down-regulation of OGT in primary hepatocytes from obese mice partially rescued the STIM1 translocation defect. It will be interesting to explore the detailed location and impact of these modifications in future studies. In silico analysis, published literature and data in dbOGAP, suggest potential target sites coinciding with the domains involved in STIM1/Orai1 interactions with Orai1 in the CAD/SOAR domain or in the polybasic motif located at the C terminal of the protein that may be critical in oligomerization and puncta formation ([@bib27]). Regardless, protein modification with O-GlcNAc is a reflection of the nutritional status, as it integrates glucose, amino acid, fatty acid and nucleotide flux through the hexosamine biosynthetic pathway (HBP) to produce *N*-acetyl-glucosamine (UDP-GlcNAc), the obligatory substrate for OGT. Hence, conditions of nutrient and substrate excess, including obesity, lead to increased cellular O-GlcNAcylation levels ([@bib52]; [@bib61]; [@bib8]; [@bib60]). Taken together, our findings demonstrate that O-GlcNAc modification of STIM1 alters organelle Ca^2+^ regulation with consequences for ER function and systemic metabolism and provide an important mechanistic insight into regulation of this critical metabolic integration point through organelle homeostasis in obesity.

Another important finding reported here is that impaired SOCE in hepatocytes by STIM1 deficiency was sufficient to induce markers of ER stress and inflammation, to impair of insulin action, increase glucose production and induce excessive lipid droplet accumulation. Recently, it has been reported that cells from patients with loss-of-function mutations in STIM1 or ORAI accumulate lipid droplets as a consequence of their inability to increase cAMP, mobilize fatty acids from lipid droplets, activate lipolysis, and oxidize fatty acids ([@bib31]). Interestingly, tamoxifen-induced whole body STIM1/2 deficiency leads to higher lipid content in the heart, muscle and liver ([@bib31]). Here, although we detected increased accumulation of lipid droplets in hepatocytes lacking STIM1 in vitro, these phenomena were not clearly observed in vivo. Hepatocyte-specific deletion of STIM1 led to a mild metabolic phenotype in vivo suggesting that the activation of compensatory systems occurs when STIM1 is deleted during development. Indeed, STIM2 expression levels were slightly increased in STIM1 deficient liver. Furthermore, in lean animals, the rest of the ER calcium handling systems are intact, which may allow maintenance of the normal equilibrium. In contrast, acute down-regulation of STIM1 showed a more marked effect on glucose homeostasis.

Finally, we show here that exogenous expression of STIM1 in primary hepatocytes from obese mice is sufficient to overcome SOCE defects and partially correct ER Ca^2+^ levels and STIM1 re-localization upon Ca^2+^ store depletion. Notably, we showed that a significant part of the exogenously expressed STIM1 is able to escape the O-GlcNAc modification, probably by a mass effect, and responds properly to ER Ca^2+^ depletion. Additionally, overexpression of STIM1 in hepatocytes from *Lep^ob/ob^* animals led to remodeling of the ER with an increase in the amount of cortical ER possibly facilitating STIM1 translocation and Orai1 coupling. Indeed, it is known that STIM1 regulates the structure of the ER through its role in Tip Attachment Complex movement ([@bib17]; [@bib55]), coordinating the growth and shrinkage of the ER tubule. Importantly, we show that upregulation of SOCE through STIM1 replenishment in the liver of obese mice results in significant metabolic benefit including improved insulin signaling and glucose tolerance and decreased lipid content likely as a result of enhanced fatty acid oxidation. When STIM1 is exogenously supplied to the liver tissue in obese mice, we also observed an increase in glycolytic gene expression. This is in agreement with recent report showing that in T cells SOCE regulates the expression of glycolytic genes through the modulation of the transcription factor NFAT ([@bib50]). Overexpression of STIM1 also led to increased SERCA levels, which is necessary for the delivery of Ca^2+^ into the ER. In fact, it is proposed and validated experimentally and computationally that an adaptive feedback loop between components of Ca^2+^ machinery exist to keep cytosolic Ca^2+^ levels under control ([@bib1]). Increased SERCA expression in the context of STIM1 overexpression may indeed be a critical component of the metabolic benefit resulting from STIM1 expression in the liver in obese mice. It is remarkable that the individual manipulation of multiple proteins involved in the maintenance of ER Ca^2+^ levels- SERCA, IP3R, and STIM1- all result in a similar phenotype. These findings underscore the importance of ER Ca^2+^ homeostasis and ER function to metabolic health, and indicate the strong potential for targeting these pathways to combat metabolic disease.

Materials and methods {#s4}
=====================

General animal care and study design {#s4-1}
------------------------------------

All in vivo studies are approved by the Harvard Medical Area Standing Committee on Animals. Unless stated otherwise, mice were maintained from 4 to 20 weeks on a 12-hour-light/12 hr-dark cycle in the Harvard T.H. Chan School of Public Health pathogen-free barrier facility with free access to water and to a standard laboratory chow diet (PicoLab Mouse Diet 20 \#5058, LabDiet). No specific power analysis was used to estimate sample size. The sample size and number of replicates for this study were chosen based on previous experiments performed in our lab and others ([@bib2]; [@bib12]).

Animal models of obesity {#s4-2}
------------------------

We used two mouse models of obesity, the leptin-deficient *Lep^ob/ob^* mouse, and HFD-induced obesity. For the former, wild-type mice in the C57BL/6J genetic background (Stock no. 000664) and *Lep^ob/ob^* mice (Stock no. 000632) were purchased from Jackson Laboratories at 6--7 weeks of age and used for experimentation between 8--12 weeks of age. For the latter, male C57BL/6J mice were purchased from Jackson Laboratories and placed on HFD (D12492: 60% kcal% fat; Research Diets) for up to 20 weeks. Control mice of the same age were fed with a low fat diet (PicoLab Mouse Diet 20 \#5053, LabDiet). In animal experiments, all measurements were included in the analysis unless they fell more than two standard deviations from the mean.

STIM1 hepatocyte-specific deficient mice {#s4-3}
----------------------------------------

Mice carrying floxed alleles for stim1 (referred here as stim1*^fl/fl^*) on a C57BL/6J background were kindly provided by Dr. Anjana Rao, La Jolla Institute for Allergy and Immunology. To generate hepatocyte-specific STIM deficient mice, stim1*^fl/fl^* mice were bred to C57BL/6J mice expressing CRE recombinase under the control of the albumin promoter (*Alb;Cre*). *Alb;Cre* -mediated recombination of floxed stim1 alleles was detected in genomic DNA by PCR. Age-matched littermates were used for the study of adult mice. For HFD studies, pups were placed on low-fat control diet (5053) for 1 week at weaning, followed by up to 20 weeks on HFD. The control chow group remained on low-fat diet. For the adenovirus-mediated stim1 down-regulation study, stim1*^fl/+^* (het) animals were crossed to each other to generate a group containing stim1*^+/+^*, stim1*^fl/+^* and stim1*^fl/fl^* homozygous mice. Pups of the three genotypes were weaned and fed a low-fat diet (5053) for 1 week followed by 4 weeks of HFD. The animals were transferred to a BL2 facility where they received adenovirus-expressing *Alb;Cre*-recombinase (1 × 10^9^ IFU/mouse) intravenously. Metabolic studies were performed between day 7--12 after infection. The animals were sacrificed after 14 days of infection for ex vivo experiments.

Adenovirus-mediated overexpression of STIM1 {#s4-4}
-------------------------------------------

For exogenous STIM1 expression, purified, de-salted adenovirus (serotype 5, Ad5) expressing STIM1-YFP was purchased from Vector BioLabs with the agreement of Dr. Alexei Tepikin from University of Liverpool. The adenovirus was administered to 8--10 week-old *Lep^ob/ob^* mice intravenously, at a titer of 1 × 10^9^ IFU/mouse. Metabolic studies were performed between day 7--12 after infection. The animals were sacrificed after 14 days of infection for ex vivo experiments.

Glucose tolerance tests {#s4-5}
-----------------------

Animals were subjected to an intraperitoneal (i.p.) glucose injection (lean: 1.5 g kg^−1^, obese: 0.5--1.0 g kg^−1^) after overnight fasting, and blood glucose levels were measured throughout the first 120 min of the metabolic response.

Liver triglyceride measurements {#s4-6}
-------------------------------

Liver tissues (approximately 100 mg) were homogenized in 1.2 mL of water. Next, 100 µL of the homogenate was transferred to a 1.5 mL tube and 125 µL of chloroform and 250 µL of Methanol were added. Samples were vortexed briefly and incubated for 5 min. Additional 125 µL of chloroform was added. Next, 125 µL of water was added and samples were vortexed and centrifuged at 3000 rpm for 20 min at 4°C. Around 150 µL of the lower phase was collected in a 1.5 mL tube and dried (evaporated) in a heated vacuum oven. Thereafter, lipids were re-suspended in 300 uL of ethanol. Triglyceride in this solution was measured by a Randox Tg Kit (cat number TR213) from Randox Laboratories.

Primary hepatocyte isolation {#s4-7}
----------------------------

Animals were anesthetized using 2 mg/ml xylazine combined with 2 mg/ml ketamine in PBS and the livers were perfused with 50 mL of buffer I (content described below) through the portal vein with an osmotic pump set to the speed of \~4 mL/min until the liver turned pale. The speed was gradually increased until \~7 mL/min afterwards. When the entire buffer I had been infused, it was substituted for 50 mL of buffer II. The buffers should be kept at \~37°C during the entire procedure. After perfusion, the primary hepatocytes were carefully released and sedimented at 500 rpm for 2 min, washed two times and suspended with Williams E medium supplemented with 5% CCS and 1 mM glutamine (Invitrogen, CA). To separate live from dead cells, the solution of hepatocytes was layered on a 30% Percoll gradient and centrifuged \~1500 rpm for 10--15 min. The healthy cells were recovered at the bottom of the tube and plated for experimentation. Buffer I contained: 11 mM Glucose; 200 µM EGTA; 1.17 mM MgSO~4~ heptahydrated; 1.19 mM KH~2~PO~4~; 118 mM NaCl; 4.7 mM KCl; 25 mM NaHCO~3~, pH 7.32. Buffer II contained: 11 mM Glucose; 2.55 mM CaCl~2~; 1.17 mM MgSO~4~ heptahydrated; 1.19 mM KH~2~PO~4~; 118 mM NaCl; 4.7 mM KCl; 25 mM NaHCO~3~; BSA (fatty acid free) 7.2 mg/mL; 0.18 mg/mL of Type IV Collagenase (Worthington Biochem Catalog: LS004188). BSA and collagenase were added immediately before use.

Glucose production assay {#s4-8}
------------------------

Primary hepatocytes derived from stim1*^fl/fl^* and stim1Δ^LIVER^ animals kept on high fat diet were isolated and incubated in fresh William's E medium with 5% fetal bovine serum (FBS) for 4 hr and thereafter, incubated in 0.1% FBS overnight. Next day, cells were washed twice and incubated with DMEM without glucose (Invitrogen) supplemented with 10 mM HEPES in the presence of 2 mM pyruvate, 2 mM glutamate and 20 mM glycerol for 4 hr. The glucose concentrations in the media were determined by Amplex Red glucose/glucose oxidase assay system (Invitrogen).

Total protein extraction, immunoprecipitation and western blotting {#s4-9}
------------------------------------------------------------------

Liver tissues were homogenized in cold lysis buffer containing 50 mM Tris-HCl (pH 7.4), 2 mM EGTA, 5 mM EDTA, 30 mM NaF, 10 mM Na~3~VO~4~, 10 mM Na~4~P~2~O~7~, 40 mM glycerophosphate, 1 % NP-40, and 1% protease inhibitor cocktail. After \~20 min incubation under mild agitation in the cold, the homogenates were centrifuged for 15 min at 9000 rpm to pellet cell debris, and protein concentrations were determined by BCA. Finally, the samples were diluted in 5x Laemmli buffer and boiled for 5 min. The protein lysates were subjected to SDS-polyacrylamide gel electrophoresis, as previously described ([@bib2]; [@bib13]). The antibodies used in this study are listed in Table 2. All the immunoblots were incubated with primary antibody overnight at 4°C, followed by incubation with secondary antibody conjugated with horseradish peroxidase (Amersham Biosciences) for 1--3 hr at room temperature. Individual membranes were visualized using the enhanced chemiluminescence system (Roche Diagnostics). Immunoprecipitation (IP): For the immunoprecipitation studies, primary antibodies against STIM1 and O-GlcNAc were cross-linked on to protein-A magnetic beads with Dimethylpimelimidate (DMP). Cells lysates were prepared in a IP lysis buffer containing 50 mM Tris-HCl (pH 7.4), 1 mM EDTA, 150 mM NaCl, 10 mM Na~3~VO~4~, 1 % NP-40, and 1% protease inhibitor cocktail and 10 µM of PugNac. Protein content was adjusted to be the same in all samples and 300--400 µg of protein were incubated with the beads overnight. The next day, samples were washed 3x with IP buffer and eluted in Laemmli buffer and boiled for 5 min. Immunoblotting was performed as described above. For the IP of Flag tagged STIM1, the lysates were incubated with anti-flag M2 magnetic beads from Sigma and eluted by competition with 3x flag peptide.

Gene expression analysis {#s4-10}
------------------------

Tissues in TRIzol (Invitrogen) were disrupted using TissueLyser (Qiagen). To obtain RNA, trizol homogenates were mixed with chloroform vortexed thoroughly and centrifuged 12000 g for 20 min at 4°C. The top layer was transferred to another tube and mixed with isopropanol and centrifuged again at 12000 g for 20 min at 4°C. The RNA found in the precipitate was washed twice with 70% Ethanol and diluted in RNAse free water. Complementary DNA was synthesized using iScript RT Supermix kit (Biorad). Quantitative real-time PCR reactions were performed in duplicates or triplicates on a ViiA7 system (Applied Biosystems) using SYBR green and custom primer sets or primer sets based on Harvard primer bank. Gene of interest cycle thresholds (Cts) were normalized to *18S ribosomal RNA* (*Rn18s)* house keeper levels by the ΔΔCt. The primers used for qPCR are listed in [Table 1](#table1){ref-type="table"}.
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###### List of primers used for qPCR measurements and sequences of the shRNA used in this study.

  ----------------------------------------------------------------------------------------------------------------
  List of SYBR green primers for real-time PCR                                     
  ---------------------------------------------- --------------------------------- -------------------------------
  stim1                                          TGAAGAGTCTACCGAAGCAGA             AGGTGCTATGTTTCACTGTTGG

  stim1                                          ACAGTGAAACATAGCACCTTCC            TCAGTACAGTCCCTGTCATGG

  stim2                                          CGAAGTGGACGAGAGTGATGA             GGAGTGTTGTTCCCTTCACATT

  orai1                                          GATCGGCCAGAGTTACTCCG              TGGGTAGTCATGGTCTGTGTC

  Itpr1                                          GGGTCCTGCTCCACTTGAC               CCACATCTTGGCTAGTAACCAG

  Atp2a2                                         CTGTGGAGACCCTTGGTTGT              CAGAGCACAGATGGTGGCTA

  Gck                                            ACCAAGCGGTATCAGCATGTG             TGGACTTCTCTGTGATTGGCA

  Hk2                                            ATGATCGCCTGCTTATTCACG             CGCCTAGAAATCTCCAGAAGGG

  Hk3                                            TGCTGCCCACATACGTGAG               GCCTGTCAGTGTTACCCACAA

  Pkm                                            GGTGGCTCTGGATACAAAGGG             CACACTTCTCCATGTAAGCGT

  Gpi                                            CTCAAGCTGCGCGAACTTTTT             GGTTCTTGGAGTAGTCCACCAG

  Pgm1                                           CAGAACCCTTTAACCTCTGAGTC           TCATTCATTCGAGAAATCCCTGC

  Pgm2                                           GCGGAATGGGATGAACAAGGA             GGTCATTGATGTAGCAAAACCCT

  Pck1                                           CTGCATAACGGTCTGGACTTC             GCCTTCCACGAACTTCCTCAC

  G6pc                                           CTGAGCGCGGGCATCATAAT              GATTCTTAGGATCGCCCAGAAAG

  Pgc1a                                          CCC TGC CAT TGT TAA GAC C         TGC TGC TGT TCC TGT TTT C

  Ppara                                          TATTCGGCTGAAGCTGGTGTA             CTGGCATTTGTTCCGGTTCT

  Cpt1                                           GCTGGAGGTGGCTTTGGT                GCTTGGCGGATGTGGTTC

  Slc25a20                                       AGTCGGACCTTGACCGTGT               GACGAGCCGAAACCCATCAG

  Scd1                                           TTC TTG CGA TAC ACT CTG GTG C     CGG GAT TGA ATG TTC TTG TCG T

  Fas                                            GGA GGT GGT GATA GCC GG TAT       TGG GTA ATC CATA GAG CCC AG

  Serbpc1                                        GGAGCCATGGATTGCACATT              GGCCCGGGAAGTCACTGT

  18S                                            AGTCCCTGCCCTTTGTACACA             CGATCCGAGGGCCTCACTA

  **Oligonucleotides for shRNA**                                                   

  stim1                                          CCGGCCGAAACATCCATAAGCTGATCTCGA\   TRCN0000193877
                                                 GATCAGCTTATGGATGTTTCGGTTTTTTG     

  stim2                                          CCGGGACGAAGTAGACCACAAGATTCTCG\    TRCN0000187841
                                                 AGAATCTTGTGGTCTACTTCGTCTTTTTTG    

  ogt                                            CCGGCCCATTTCTTTCAGCAGAAATCTCGA\   TRCN0000110395
                                                 GATTTCTGCTGAAAGAAATGGGTTTTTG      
  ----------------------------------------------------------------------------------------------------------------
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###### List of antibodies used in this study.

  Antibodies used in western blots                                                                     
  ---------------------------------- ----------------------------------------------------------------- ------------
  STIM1                              Cell signaling                                                    \#4916
  STIM2                              Cell signaling                                                    \#4917
  ORAI1                              Sigma                                                             SAB3500126
  SERCA2b                            Cell Signaling                                                    \#4388
  pJNK                               Cell signaling                                                    \#81E11
  peIF2alpha                         Cell signaling                                                    \#3597
  CHOP                               Cell Signaling                                                    mab\# 2895
  pAKT                               Santa Cruz                                                        7985R
  AKT                                Santa Cruz                                                        8312
  IR                                 Santa Cruz                                                        711
  pIR                                Calbiochem                                                        407707
  OGT                                Cell Signaling                                                    \#5368
  O-GlcNAc (CTD110.6)                Cell Signaling                                                    \#12938
  Flag M2                            Sigma                                                             SLBD9930
  pCamKII                            Cell Signaling                                                    \#12716
  β-tubulin                          Abcam                                                             ab 21058
  pSTIM1                             provided by Dr. Martin-Romero, University of Extremadura, Spain   

Endogenous protein staining and confocal imaging {#s4-11}
------------------------------------------------

For thapsigargin (Tg) stimulation, primary hepatocytes or Hepa1-6 cells were seeded on 3.5 mm round glass dishes (1.5 mm) in Williams Medium in the presence of 5% CCS overnight at 37°C, 5% CO~2~. The following morning, cells were washed, and in the afternoon they were incubated for a few minutes in Ca^2+^-free medium (described in the Ca^2+^ imaging section) followed by 1 µM Tg treatment (or vehicle, DMSO) for the duration indicated in the figure legends. Cells were fixed with 4% paraformaldehyde for 10 min at room temperature (RT) and washed 3x in PBS, before a 20 min permeabilization using 0.2% Triton-X100 in 2% BSA at RT. Primary antibodies were diluted 1:200 for STIM1 (Cell Signaling \#4916), 1:100 for STIM2 (Cell Signaling \#4917), for Na^+^/K^+^ ATPase α−1 -Alexa Fluor 488 (Sigma \#16--243) and for Anti-KDEL antibody, Alexa fluor 488 (Abcam, ab184819) in PBS and the cells were incubated in this solution over night at 4°C in the dark. The next day, cells were washed 3x, including one long wash for more than 10 min. Secondary antibody was diluted 1:2500 in PBS, and the cells were incubated with it at RT for 1 hr in the dark. The cells were washed 3x, including one long wash, and if needed, Hoechst was used as nuclear marker, diluted 1:1000 in PBS for 10 min at RT. For the experiments described in [Figure 1---figure supplement 1D](#fig1s1){ref-type="fig"}, [Figure 1---figure supplement 2A,B](#fig1s2){ref-type="fig"} cells were imaged at the Confocal and Light Microscopy Core Facility at the Dana Farber Cancer Institute with a Yokogawa CSU-X1 spinning disk confocal system (Andor Technology, South Windsor, CT) with a Nikon Ti-E inverted microscope (Nikon Instruments, Melville, NY), using a 60x or 100x Plan Apo objective lens with a Hamamatsu OrcaER camera. Andor iQ software (Andor Technology, South Windsor, CT) was used for acquisition parameters, shutters, filter positions and focus control. For [Figures 1C, D](#fig1){ref-type="fig"}, [3G](#fig3){ref-type="fig"} and [5D](#fig5){ref-type="fig"}, cells were imaged at the Harvard Medical School Imaging Core with a Yokogawa CSU-X1 spinning disk confocal system (Andor Technology, South Windsor, CT) with an iXon EMCCD camera and Metamorph was the software used for acquisition parameters, shutters, filter positions and focus control. For [Figure 2H](#fig2){ref-type="fig"} cells were image with a Yokogawa CSU-X1 spinning disk confocal system (Andor Technology, South Windsor, CT) with a Nikon Ti-E inverted microscope (Nikon Instruments, Melville, NY), using a 60x or 100x Plan Apo objective lens with Zyla cMOS camera and NIS elements software was used for acquisition parameters, shutters, filter positions and focus control.

Confocal image analysis {#s4-12}
-----------------------

Image analysis was performed using Fiji software. All the images in the same experiment were analyzed using the same parameters. For [Figure 1E](#fig1){ref-type="fig"}, puncta number was counted using a custom made macro. After background subtraction of 15, images were subject to 'Filter Gaussian blur' of 1.00 and a threshold was set to define puncta from background signal. In order to localize the individual puncta 'Find Maxima' tool was used and puncta were counted using 'Analyze Particles' tool. For [Figure 2J](#fig2){ref-type="fig"}, images were background subtracted and single cells or groups of cells either expressing OGT or not (identified by RFP expression), were cropped from the original image. Puncta above a threshold of 50 were counted using 'Analyze Particles', and normalized to number of cells in the field. Puncta pixel intensities: For [Figure 1F](#fig1){ref-type="fig"} and [Figure 1---figure supplement 2B](#fig1s1){ref-type="fig"}, a 125 × 125 pixels box was placed in a representative region of the cell and pixel intensities were recorded in the entire box using a custom made macro. Intensities were distributed into a histogram with R, and plotted in Prism. No further normalization was performed, as the same number of pixels was evaluated in all the images.

Plot profile in [Figures 1G](#fig1){ref-type="fig"}, [2L](#fig2){ref-type="fig"} and [5E](#fig5){ref-type="fig"}: A thin box of 40 × 250 pixels was placed across the cell and the average intensity contained in the box was plotted as a profile with Fiji. Edge/cyto measurements: for [Figures 1H](#fig1){ref-type="fig"}, [2N](#fig2){ref-type="fig"},[5D](#fig5){ref-type="fig"}, [Figure 1---figure supplement 2B](#fig1s2){ref-type="fig"}: A small box was hand-drawn at a region of the edge of the cell (at the PM), and the same size box was placed right next to the edge, in the cytoplasmic region. The mean STIM signal across each box was recorded, and the ratio between the reading at the edge of the cell and in the cytoplasm was derived after background signal subtraction. Such pairs of boxes were drawn in four representative places in each cell, from 2 to 5 cells per field. Areas were chosen only on cell membranes containing neighbor cells.

Total internal reflection fluorescence (TIRF) microscopy {#s4-13}
--------------------------------------------------------

For the TIRF images, cells were stained as described above using anti-STIM1 antibody and anti- Na^+^/K^+^ ATPase α−1, Alexa Fluor 488 antibody to stain the PM. In each experiment epifluorescence images were acquired and the PM marker was used to define the PM area for the TIRF imaging. The images were acquired a Zeiss Elyra PS.1 microscope with a 60 or 100 × 1.46 N.A. oil immersion TIRF objective (Carl Zeiss GmbH, Germany) in TIRF mode with an Andor EM-CCD camera (512 × 512 pixels) at the Harvard center for Biological Imaging, Cambridge, MA.

Cytosolic Ca^2+^imaging using Fura-2 AM and Fluo-4 {#s4-14}
--------------------------------------------------

Cells were loaded with 4 μM Fura-2AM and 1 µM Pluronic F-127 in HBSS for \~60 min at room temperature. Before imaging, the cells were washed and kept in a medium containing 10 mM Hepes, 150 mM NaCl, 4 mM KCl, 2 mM CaCl~2~, 1 mM MgCl~2~, 10 mM D-glucose, pH 7.4. Ca^2+^-free medium was prepared similarly to the buffer described above, in the absence of CaCl~2~ and in the presence of 2 mM EGTA and 3 mM MgCl~2~. Cells were stimulated with 1 µM Tg for indirect ER Ca^2+^ measurements, and in some cases supplemented with 100 µM 2-APB for SOCE inhibition. Ratiometric Fura-2AM imaging was performed by alternatively illuminated with 340 and 380 nm light for 250 ms (Lambda DG-4; Sutter Instrument Co.), using an Olympus IX70 with 40x objective. Emission light \>510 nm was captured using a CCD camera (Orca-ER; Hamamatsu Photonics). Both channels were collected every 5 s, background corrected and analyzed with Slidebook and custom-made R-scripts. For the Fluo-4 experiments described in [Figure 2J](#fig2){ref-type="fig"}, the same procedure described above as used except that the cells were incubate with Fluo-4 for 30 min to 1 hr. The images were acquired on a Leica SP8X and LAS X software was used for acquisition parameters, shutters, filter positions and focus control.

Cell culture {#s4-15}
------------

Loss of function experiments were performed in Hepa1-6 cells (a mouse hepatocyte cell line from ATCC, derivative of the BW7756 mouse hepatoma that arose in C57/L mouse) for STIM1, STIM2 and ORAI1. This cell line was negative for mycoplasma testing. Five different shRNA sequences targeting different regions of each gene were obtained from *MISSION* shRNA Library (Sigma) along with the Scramble shRNA control. Stable cell lines were generated by lentiviral infection of Hepa1-6 cells overnight in media (DMEM and 10% CCS and polybrene). After infection cells were incubated in growth media (DMEM and 10% CCS) and selected with 3 µg/µl puromycine. The knockdown efficiency of each shRNA was evaluated by western blot analysis and the experiments were done with the sequence that generated the highest efficiency. Cells were frozen at passage two after selection and fresh cells were thawed for each experiment. The sequences of the shRNA used in the study are listed in [Table 1](#table1){ref-type="table"}. For the overexpression of OGT, a hOGT/RFP co-expression plasmid was generated using a self-cleaving P2A peptide linker. RFP was first cloned into pcDNA6 Myc/His B (Life Technologies V22120) at BamHI/XhoI sites. OGT-P2A was generated by PCR (F: 5'-CCC GGT ACC GCC ACC ATG GCGTCTTCCGTGGGCAA; R: 5'- CCC GGA TCC AGG TCC AGG GTT CTC CTC CAC GTC TCC AGC CTG CTT CAG CAG GCT GAA GTT AGT AGC TCC GCT TCC TGCTGACTCAGTGACTTC) and cloned into the above vector at KpnI/BamHI sites.The OGT-RFP plasmid was transfected into, cells using lipofectamine 2000 overnight in OptiMEM media and the experiment done after 36--48 hr after transfection. For the STIM1-flag pull downs, 3xFLAG-mSTIM1 was generated by PCR (F: 5'- CCC GGATCC GCC ACC **ATG** *GAC TAC AAA GAC CAT GAC GGT GAT TAT AAA GAT CAT GAC ATC GAT TAC AAG GAT GAC GAT GAC AAG* GATGTGTGCGCCCGTCTTGCCCTGT; R: 5'- CCC GCGGCCGC TTA CTA CTTCTTAAGAGGCTTCTTAA) and cloned into pENTR1A no CCDB vector (Addgene \#17398) at BamHI/NotI sites and then transferred to pLenti CMV Puro DEST (w118-1) (Addgene \# 17452) using Gateway LR Clonase II Enzyme Mix (Life Technologies 11791). STIM1-flag was transfected in HEK293T cells and after 24--36 hours cells were trated with 3 ug/mL of puromycin for selection and a stable cell line was generated.

Insulin treatment in vivo and in vitro and lipid loading {#s4-16}
--------------------------------------------------------

For insulin signaling studies, cells were serum deprived for 4 hr before stimulus with 3 nM of insulin for 3 and 6 min. Cells were washed in ice-cold PBS and snap-frozen in liquid nitrogen. For the insulin infusions in vivo, following 6 hr of food withdrawal, mice were anaesthetized with an intraperitoneal injection of 2 mg/ml xylazine and 2 mg/ml ketamine, and insulin (0.75 IU kg^−1^) or phosphate buffered saline (PBS) in 200 µl volume was infused into the portal vein. Three minutes after infusion, tissues were removed and frozen in liquid nitrogen and kept at --80°C until processing. For lipid loading experiments primary hepatocytes were isolated in the morning and kept in Williams E medium. After the cells were settled, Williams medium containing 1 mM Oleic acid and 40 µM palmitic acid was added to the culture. Cells before and after 16 hr of lipid loading and stained with BODIPY and Hoechst to visualize lipid droplets and nucleus, respectively.

Transmission electron microscopy (TEM) {#s4-17}
--------------------------------------

For TEM, primary hepatocytes were fixed in a 1:1 ratio in a fixative buffer and Williams Medium. The fixative buffer contained: 4 parts of FP stock (2.5% PFA, 0.06% picric acid in 0.2M Sodium Cacodylate buffer pH 7.4) and 1 part of 25% glutaraldehyde for at least 2 hr. The samples were then placed in propyleneoxide for 1 hr and infiltrated in a 1:1 mixture of propyleneoxide and TAAB 812 Resin mixture (Marivac Canada Inc. St. Laurent, Canada). Sectioning and imaging: ultrathin sections (about 90 nm) were generated using a Reichert Ultracut-S microtome, JEOL microscope. Images were recorded with an AMT 2 k CCD camera. For the STIM-HRP labeled cells, primary hepatocytes were infected with adenovirus expressing STIM1-HRP. The construct was kindly provided by Dr. Lewis from Stanford University and cloned in an adenovirus (serotype 5, Ad5). Primary hepatocytes were fixed in a buffer containing 2% glutaraldehyde in 0.1 M sodium cacodylate at room temperature for 1 hr, then quickly moved to ice and washed with 0.1 M sodium cacodylate buffer for 10 min. HRP was visualized with 0.5 mg ml diaminobenzidine and 0.03% hydrogen peroxide in 0.1 M sodium cacodylate buffer for 5 min-20min. The reaction was stopped by five washes with cold 0.1 M sodium cacodylate buffer.
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In the interests of transparency, eLife includes the editorial decision letter and accompanying author responses. A lightly edited version of the letter sent to the authors after peer review is shown, indicating the most substantive concerns; minor comments are not usually included.

\[Editors' note: this article was originally rejected after discussions between the reviewers, but the authors were invited to resubmit after an appeal against the decision.\]

Thank you for submitting your work entitled \"Defective STIM-mediated Store Operated Ca^2+^ Entry in Hepatocytes Leads to Metabolic Dysfunction in Obesity\" for consideration by *eLife*. Your article has been reviewed by three peer reviewers, one of whom is a member of our Board of Reviewing Editors, and the evaluation has been overseen by a Senior Editor. The reviewers have opted to remain anonymous.

Our decision has been reached after consultation between the reviewers. Based on these discussions and the individual reviews below, we regret to inform you that your work will not be considered further for publication in *eLife*.

It was agreed that the manuscript was very well crafted and written and the fundamental observation that SOCE is important for hepatic calcium homeostasis and glucose tolerance is solid. However, there are many basic questions remaining and the underlying mechanisms have not yet been clearly addressed. The reviewers raised many basic issues and on balance many of these would have to be clarified to raise the level of scientific impact to the point where the paper could be considered for *eLife*.

*Reviewer \#1:*

This manuscript describes a novel connection between obesity associated glucose intolerance and hepatic calcium transport into the ER mediated by the SOCE system. The concept that glucose intolerance in obesity is promoted by dysfunction of STIM mediated by O-glycNAcylation is of significant interest. However, there are several key points that the authors should consider in order to more completely document and strengthen this hypothesis:

1\) It is not clear that the glucose intolerance (abnormal GTT) induced by the manipulations (STIM KO and over expression in liver) relates to systemic insulin resistance versus alterations in insulin, glucagon or other hormones during the GTT. Serum hormones and hyperinsulinemic clamp studies must be carried out to show that STIM KO suppresses insulin mediated inhibition of hepatic glucose output in vivo. The limited data indicates some reduction in insulin stimulated Akt, but it is not clear whether this translates to actual glucose production.

2\) The authors suggest that overnutrition is associated with hyper-glyNAcylated proteins as is hyperglycemia. If the hyper-glyNAcylated STIM1 is promoted by hyperglycemia, then this is a secondary effect of the obesity and insulin resistance and not the cause it would seem. How early in the hyperglycemic stage of the ob/ob mouse is STIM1 translocation observed to be defective? Does it only occur well after the extreme hyperinsulinemia and hyperglycemia is established in these ob/ob animals? Does it occur early or late in HFD mice?

3\) The KO and overexpression of STIM1 in liver don\'t mimic alterations in the obese state, since STIM1 expression is not altered in the ob/ob mouse, but rather its translocation. Under the overexpression conditions, one might predict that STIM1 is also hyper-glyNAcylated and therefore also defective. Is that the case, or does it escape this modification when highly expressed? In order to document that hyper-glyNAcylated STIM1 is the cause of altered calcium dynamics in the obese state, one would have to specifically block this modification only in STIM1, a difficult experimental feat. Thus, the hypothesis at this point is rather weakly supported as it is \"guilt by association\" rather than demonstrated causation.

Reviewer \#2:

The authors present an interesting line of evidence that describes Ca^2+^ handling as a key mechanism underlying hepatic endoplasmic reticulum (ER) stress in obesity. They describe that hepatocytes from obese mice displayed significantly diminished store operated Ca^2+^ entry (SOCE) as a result of impaired STIM1 translocation, which was associated with aberrant STIM1 O-GlycNAcylation.

Primary hepatocytes deficient in STIM1 exhibited elevated cellular stress as well as impaired insulin action and increased lipid droplet accumulation and mice with acute liver deletion of STIM1 displayed systemic glucose intolerance. Conversely, over-expression of STIM1 in obese mice led to increased SOCE, which was sufficient to improve systemic glucose tolerance.

Reviewer Synopsis:

Overall the study is of potential significant interest to the field and the experiments described are well-performed. The major conceptual advance is that Ca^2+^ balance regulation by SOCE in hepatocytes contributes to metabolic homeostasis. Major comments are listed below:

1\) How does Ca^2+^ balance regulates lipid accumulation in hepatocytes?

In [Figure 3D](#fig3){ref-type="fig"}, the authors show that STIM1 deficiency leads to accumulation of lipids following treatment with palmitic and oleic acid in vitro. Is the increased accumulation of lipids in hepatocytes due to the increase entry of fatty acids or a decreased fatty acid oxidation? in vivo, there was no increase in lipid accumulation in liver of mice with hepatocyte-specific deletion of STIM1. This could be due to a compensatory increase in STIM2. Therefore, silencing both STIM1 and 2 could reproduce in vivo the increased lipid accumulation in liver. The authors could use shRNA adenovirus targeting STIM1/2 and measure lipid accumulation. On the other hand, it could be due to the fact that the mice used in the experiment were fed a high fat diet and already display hepatic steatosis, which would mask the effect of STIM1 deficiency. Using mice fed a normal diet with deletion of STIM1 would be a better model to measure an increased lipid accumulation and glucose intolerance exacerbation.

2\) In [Figure 4](#fig4){ref-type="fig"}, STIM1 overexpression in ob/ob mice improves glucose tolerance and insulin response, and decreases expression of gluconeogenic genes while increasing the expression of genes involved in glycolysis. What is the effect of STIM1 overexpression on hepatic steatosis: is there more TG accumulation in liver? Is the expression of genes involved in de novo lipogenesis, lipid uptake, FA oxidation affected by STIM1 overexpression?

Reviewer \#3:

Pers and colleagues present data linking obesity with defective calcium influx and endoplasmic reticulum dysfunction in mouse hepatocytes. In general, the manuscript is well written and the experimental logic is sound. The authors conclude that STIM1 trafficking from the ER to plasma membrane is perturbed in hepatocytes from obese mice due to aberrant/increased O-GycNAcylation. This coincides with increased ER stress and a variety of metabolic defects that are interesting but not at all surprising considering the very well-documented connection between ER calcium homeostasis and ER function. The most exciting portion of the manuscript is the demonstration that over-expression of STIM1-YFP rescues several of the metabolic defects observed in obese mice.

Unfortunately, it is not at all clear why this is the case or if it even involves increased STIM1 activity/SOCE in the obese hepatocytes. The data indicate that STIM1-YFP overexpression severely perturbs or alters ER morphology potentially allowing STIM1 to interact with Orai1 at the plasma membrane, essentially by chance. However, STIM1-YFP appears to be quite different than endogenous STIM1 as it is not affected by thapsigargin. Many questions remain: Is overexpressed STIM1 also O-GlcNAc-ylated? Is ER calcium homeostasis improved? Does over-expression of any ER-localized transmembrane protein provide relief in obese mouse hepatocytes? Why does overexpression of STIM1 result in increased transcription of Orai1 mRNA, SERCA mRNA? STIM1 overexpression may simply activate a compensatory response to ER dysfunction such as the UPR which improves the documented metabolic defects. Also, why/how does STIM1 overexpression increase glycolysis gene expression?

While the data is beautifully presented, the impact of the paper\'s findings are modest at best. The conclusion that SOCE is an important mechanism for healthy hepatocyte Ca^2+^ homeostasis and systemic metabolic control is of moderate interest.
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Author response

\[Editors' note: the author responses to the first round of peer review follow.\]

> Reviewer \#1:
>
> This manuscript describes a novel connection between obesity associated glucose intolerance and hepatic calcium transport into the ER mediated by the SOCE system. The concept that glucose intolerance in obesity is promoted by dysfunction of STIM mediated by O-glycNAcylation is of significant interest. However, there are several key points that the authors should consider in order to more completely document and strengthen this hypothesis:
>
> 1\) It is not clear that the glucose intolerance (abnormal GTT) induced by the manipulations (STIM KO and over expression in liver) relates to systemic insulin resistance versus alterations in insulin, glucagon or other hormones during the GTT. Serum hormones and hyperinsulinemic clamp studies must be carried out to show that STIM KO suppresses insulin mediated inhibition of hepatic glucose output in vivo. The limited data indicates some reduction in insulin stimulated Akt, but it is not clear whether this translates to actual glucose production.

Thank you for this thoughtful question. To address this issue, we measured fasting insulin levels in mice in which STIM1 was down regulated (STIM1KD), and found no differences compared with the WT controls (new [Figure 3I](#fig3){ref-type="fig"}). We had very limited serum samples from these animals and unfortunately were not able to determine other hormones during GTT. However, we decided to directly determine whether the absence of STIM1 influences hepatocyte glucose production, by measuring glucose production in primary hepatocytes isolated from WT and STIM1 deficient animals. As shown in the new [Figure 3E](#fig3){ref-type="fig"}, glucose production stimulated by gluconeogenic substrates (pyruvate, glutamine and glycerol) was significantly higher in STIM1 deficient animals compared with WT. These data indicate that the effect of STIM1 deficiency in hepatocytes does in deed translate to higher glucose production.

While we agree that hyperinsulinemic clamps are the gold standard method for determination of glucose fluxes, it is not possible to perform these experiments in a timely manner considering the complexity and time demands. However, our new results showing significantly increased glucose production from primary hepatocytes with STIM1-deficiency add an additional and direct measure from hepatocytes to support our conclusions.

> 2\) The authors suggest that overnutrition is associated with hyper-glyNAcylated proteins as is hyperglycemia. If the hyper-glyNAcylated STIM1 is promoted by hyperglycemia, then this is a secondary effect of the obesity and insulin resistance and not the cause it would seem. How early in the hyperglycemic stage of the ob/ob mouse is STIM1 translocation observed to be defective? Does it only occur well after the extreme hyperinsulinemia and hyperglycemia is established in these ob/ob animals? Does it occur early or late in HFD mice?

We thank the reviewer for these comments. To answer this question, we followed a cohort of animals fed chow or HFD for 3, 5, 7 and 11 weeks. We choose to perform the experiment using HFD obesity model instead of the ob/ob because in leptin deficient animals, the hyperglycemia and hyperinsulinemia appears very early on (as early as 4 weeks) which would make it difficult to uncouple the STIM defects from the acute metabolic alterations found in this mouse model.

As can be seen in [Figure 1---figure supplement 2C](#fig1s2){ref-type="fig"}, in HFD fed mice, body weight and insulin levels started to rise after 5 weeks of high fat feeding, reaching maximal levels after 7 weeks of HFD. However, the glucose levels were not significantly changed during this time frame.

We then analyzed STIM1 translocation in hepatocytes isolated from these mice. As shown in [Figure 1---figure supplement 2A and 2B](#fig1s2){ref-type="fig"}, at 3 weeks time point on HFD we detected some degree of translocation at the baseline (non-treated condition) indicating that short term HFD is sufficient to induce decreased levels of calcium in the ER, which is the driving force for STIM translocation. However, at this time point, STIM1 translocation upon TG stimulation was not significantly impaired compared with cells derived from chow fed animals. The defect in TG ‐induced STIM1 translocation was first observed in hepatocytes isolated from mice after 5 weeks of HFD, and was more pronounced at the 7 and 11-week timepoints ([Figure 1---figure supplement 2A and 2B](#fig1s2){ref-type="fig"}). Based on these findings, we conclude that the defect in STIM1 translocation is not related to hyperglycemia and starts before the frank hyper-insulinemia found in obesity at least in the HFD model [Figure 1---figure supplement 2C](#fig1s2){ref-type="fig"}. We additionally observed that the O-GlcNAcylation levels of STIM1 are progressively increased in hepatocytes from HFD fed animals starting from 3 week on HFD ([Figure 2---figure supplement 1C](#fig2s1){ref-type="fig"}).

> 3\) The KO and overexpression of STIM1 in liver don\'t mimic alterations in the obese state, since STIM1 expression is not altered in the ob/ob mouse, but rather its translocation. Under the overexpression conditions, one might predict that STIM1 is also hyper-glyNAcylated and therefore also defective. Is that the case, or does it escape this modification when highly expressed? In order to document that hyper-glyNAcylated STIM1 is the cause of altered calcium dynamics in the obese state, one would have to specifically block this modification only in STIM1, a difficult experimental feat. Thus, the hypothesis at this point is rather weakly supported as it is \"guilt by association\" rather than demonstrated causation.

To answer this reviewer's question we used adenovirus-mediated gene delivery to overexpress STIM1-YFP in primary hepatocytes derived from obese (ob/ob) animals. We immunoprecipitated O-GlcNac modified proteins in these cells using an OglcNac specific antibody and performed immunoblot to detect STIM1 among these proteins. As it can be seen in [Figure 4F](#fig4){ref-type="fig"}, STIM1-‐YFP overexpression resulted in an approximately 20-fold increase in the expression of STIM1 protein. However, the amount of STIM1 observed in the O-‐GlcNac pull-‐down was not proportionally increased, indicating that a majority of the overexpressed STIM1 is able to "escape" this post translation modification.

So far, we have not been able to make satisfactory progress in determining the exact sites of STIM1 O-GlcNacylation in order to perform site direct mutagenesis. However, to determine if blocking this modification could rescue the defect in STIM1 translocation, we used an adenovirus expressing an shRNA against OGT to down-regulate OGT and therefore suppress O-GlcNacylation in primary hepatocytes from ob/ob animals. As shown in [Figure 2K and L](#fig2){ref-type="fig"}, adenovirus mediated expression of shRNA against OGT lead to 60% down-regulation in OGT and overall OglcNacylation. Importantly, down-‐regulation of OGT lead to increased levels of STIM1 translocation in response Tg ([Figure 2M and N](#fig2){ref-type="fig"}). These results strengthen our conclusion that O-GlcNacylation is an important factor driving the defects in STIM translocation in obese cells.

> Reviewer \#2:
>
> The authors present an interesting line of evidence that describes Ca^2+^ handling as a key mechanism underlying hepatic endoplasmic reticulum (ER) stress in obesity. They describe that hepatocytes from obese mice displayed significantly diminished store operated Ca^2+^ entry (SOCE) as a result of impaired STIM1 translocation, which was associated with aberrant STIM1 O-GlycNAcylation.
>
> Primary hepatocytes deficient in STIM1 exhibited elevated cellular stress as well as impaired insulin action and increased lipid droplet accumulation and mice with acute liver deletion of STIM1 displayed systemic glucose intolerance. Conversely, over-expression of STIM1 in obese mice led to increased SOCE, which was sufficient to improve systemic glucose tolerance.
>
> Reviewer Synopsis:
>
> Overall the study is of potential significant interest to the field and the experiments described are well-performed. The major conceptual advance is that Ca^2+^ balance regulation by SOCE in hepatocytes contributes to metabolic homeostasis. Major comments are listed below:
>
> 1\) How does Ca^2+^ balance regulates lipid accumulation in hepatocytes?
>
> In [Figure 3D](#fig3){ref-type="fig"}, the authors show that STIM1 deficiency leads to accumulation of lipids following treatment with palmitic and oleic acid in vitro. Is the increased accumulation of lipids in hepatocytes due to the increase entry of fatty acids or a decreased fatty acid oxidation?

Thank you for this interesting question. The effects of STIM1 deficiency on lipid metabolism have been addressed recently by Maus et al., 2016. In this paper, the authors show that SOCE regulates lipolysis through the production of cyclic AMP and the expression lipases ATGL and HSL as well as the transcriptional regulators of fatty acid oxidation such as PGC-1a and PPARa. They also show, similar to us, that cells deficient in STIM1 accumulate lipid droplets. We have incorporated this reference into our discussion.

> In vivo, there was no increase in lipid accumulation in liver of mice with hepatocyte-specific deletion of STIM1. This could be due to a compensatory increase in STIM2. Therefore, silencing both STIM1 and 2 could reproduce in vivo the increased lipid accumulation in liver. The authors could use shRNA adenovirus targeting STIM1/2 and measure lipid accumulation. On the other hand, it could be due to the fact that the mice used in the experiment were fed a high fat diet and already display hepatic steatosis, which would mask the effect of STIM1 deficiency. Using mice fed a normal diet with deletion of STIM1 would be a better model to measure an increased lipid accumulation and glucose intolerance exacerbation.

Thank you for this suggestion. As suggested, we have measured glucose tolerance and TG content in the livers of STIM1 deficient animals under chow diet and we were not able to detect significant differences between the genotypes on the overall TG content and glucose tolerance. We added a line referring to this data in the text. We also performed a short term HFD study (6 weeks on HFD) and observed that in this case STIM1 deficient animals exhibited a modest but significant, impairment in a glucose tolerance test compared with the WT controls. Additionally, these animals showed decreased insulin signaling as measured by pIR and pAKT. In this context there were no significant differences in Tg content, although a tendency to be higher was detected ([Figure 3---figure supplement 2E](#fig3s2){ref-type="fig"}).

Interestingly, although we haven't observed overall changes in lipid accumulation in the liver specific STIM1 deficient animals, we have noticed that these animals show higher content of microvesicular steatosis compared with controls where the majority of the lipid droplets are presented as large droplets ([Figure 3---figure supplement 2D](#fig3s2){ref-type="fig"}). Although not addressed in this paper, previous reports have shown that microsteatosis are associated with mitochondrial dysfunction (Tandra et al., 2011), which would fit with the findings from Maus et al., 2016, showing that STIM deletion affects mitochondrial fatty acid oxidation.

As the reviewer's pointed out, the interpretation of the phenotype of liver specific STIM1 deficient animals is complex. Under chow diet, the absence of a phenotype in STIM1 deficient animals under chow diet could possibly be due to a compensation of STIM2. As the animals progress on HFD, as shown in our time course analysis ([Figure 1---figure supplement 2A and B](#fig1s2){ref-type="fig"}), STIM becomes deficient, so the comparison of the WT on HFD (STIM deficiency) with a KO on a HFD (STIM absence) is hard to interpret. We agree that possibly a knockdown of both STIM1 and STIM2 in the liver could provide answers for this matter, but given the time frame of this experiments, we opted to focus only on STIM1.

> 2\) In [Figure 4](#fig4){ref-type="fig"}, STIM1 overexpression in ob/ob mice improves glucose tolerance and insulin response, and decreases expression of gluconeogenic genes while increasing the expression of genes involved in glycolysis. What is the effect of STIM1 overexpression on hepatic steatosis: is there more TG accumulation in liver? Is the expression of genes involved in de novo lipogenesis, lipid uptake, FA oxidation affected by STIM1 overexpression?

We have now measured TG content in liver from 3 different cohorts of ob/ob mice overexpressing STIM1-‐YFP and GFP control. As shown in [Figure 5H](#fig5){ref-type="fig"}, TG content was significantly decreased in livers overexpressing STIM1 compared with controls. Accordingly, mRNA expression of CPT1 and acadvl1, genes involved fatty acid oxidation, are increased in STIM1-‐YFP overexpression livers compared with controls, while no changes were observed in genes involved in lipogenesis ([Figure 5---figure supplement 1A and B](#fig5s1){ref-type="fig"}).

> Reviewer \#3:
>
> \[...\] The data indicate that STIM1-‐YFP overexpression severely perturbs or alters ER morphology potentially allowing STIM1 to interact with Orai1 at the plasma membrane, essentially by chance. However, STIM1-‐YFP appears to be quite different than endogenous STIM1 as it is not affected by thapsigargin.

We thank the reviewer for these comments. We agree that determining the response of the STIM1-YFP is a critical control and we have performed this experiment and demonstrated its proper responsiveness in the original manuscript ([Figure 4C and D](#fig4){ref-type="fig"}). We recognize that our description of the STIM1-‐YFP experiments and the effect on SOCE may not have been sufficiently emphasized in the first version of the manuscript. As shown in [Figure 4C](#fig4){ref-type="fig"}, and quantified in [Figure 4D](#fig4){ref-type="fig"}, STIM1-YFP does respond to thapsigargin similarly to endogenous STIM1. To clarify this point further, we are now adding a live movie showing this response (Movie1) in the revised manuscript. Additionally, the STIM1-‐ YFP construct has been used multiple times in the literature, and shown to recapitulate the action of the endogenous protein (Sauc et al., 2015; Sundivakkam et al., 2012; Darbellay et al., 2010; Liou et al., 2005). The alterations in the ER morphology promoted by overexpression of STIM1 is likely related to the role of STIM1 as an ER structural protein. In resting cells STIM1 binds the plus-‐end-‐tracking protein (+TIP) of microtubules, anchoring the ER to the microtubules. However, to mediate SOCE, STIM1-YFP disconnects from the microtubules and needs to traffic within the ER, and this movement is driven by ER calcium depletion, phosphorylation and interaction with other proteins. To better clarify this process, we re-organize these data and its description accordingly in the revised manuscript.

> Is overexpressed STIM1 also O-‐GlcNAcylated?

We thank the reviewer for this question. This issue was similarly raised by Reviewer 1. To address this reviewer's question we used adenovirus-‐mediated gene delivery to express STIM1-‐YFP in primary hepatocytes derived from obese (ob/ob) animals. We immunoprecipitated O-GlcNac modified proteins in these cells using an O-GlcNac specific antibody and performed immunoblot experiments to detect STIM1 among these proteins. As can be seen in [Figure 4F](#fig4){ref-type="fig"}, STIM1-YFP overexpression resulted in an approximately 20-fold increase in the expression of STIM1 protein. However, the amount of STIM1 observed in the O-GlcNac pull-down was not proportionally increased, indicating that a majority of the overexpressed STIM1 is able to "escape" this post translational modification.

> Is ER calcium homeostasis improved?

As shown in [Figure 4G](#fig4){ref-type="fig"}in the revised manuscript, overexpression of STIM1 leads to increased ER Ca^2+^content and SOCE. Does over-‐expression of any ER-localized transmembrane protein provides relief in obese mouse hepatocytes?

We would not anticipate that this would be the case. For example, in our earlier work (Yang et al., 2015) overexpression of IRE1, an ER trans-membrane protein, does not change the metabolic status of ob/ob animals while the overexpression of a mutant IRE1 resistant to nitrosylation does. Another example was reported recently by our group where the overexpression of the ER bound transcription factor Nrf1/Nfe2L1 revert steatosis in a model of hyperlipidemia/hypercholesterolemia, but overexpression of ER-bound transcription-inactive mutant versions of this protein does not affect steatosis (Widenmaier et al., 2017).

These are two clear examples that the relief is related to the function of the protein rather than an unspecific effect. In the current study, we have demonstrated that exogenously expressed STIM1 is functional and responds to calcium fluxes in a similar way to the endogenous protein. Taken together, we do not think that any ER-localized transmembrane protein is capable of generating the relief.

> Why does overexpression of STIM1 result in increased transcription of Orai1 mRNA, SERCA mRNA?

Thank you for this interesting question. Abell et al., 2011 have shown experimentally and computationally that there is a tight regulation and adaptation between the different components of cellular calcium homeostasis; Knockdown of one of the players (i.e. SERCA, STIM1, PMCA, IP3R) will result in a compensatory regulation of the other proteins to maintain calcium homeostasis. Although Abell et al. did not directly assess the effect of overexpression of these calcium-‐regulating proteins, based on their knockdown experiments they formulated the hypothesis that an adaptive feedback loop exists between the components of the cellular calcium homeostasis. Hence, the increased SERCA and Orai levels in STIM1-‐OE hepatocytes, could likely be a compensatory response to restore cytosolic calcium levels which otherwise will be detrimental for the cell. We have incorporated explanation of this point into the discussion.

> Also, why/how does STIM1 overexpression increase glycolysis gene expression?

It has been shown very recently that in T cells, SOCE controls the expression of glycolytic genes specifically through the regulation of the transcriptional factor NFAT (Vaeth et al., 2017). Although not experimentally addressed in our paper, a similar mechanism could exist in hepatocytes. We added a line of discussion about these findings in our manuscript.

References:

Tandra S, Yeh MM, Brunt EM, Vuppalanchi R, Cummings OW, Ünalp-‐Arida A, Wilson LA, Chalasani N. Presence and significance of microvesicular steatosis in nonalcoholic fatty liver disease. J Hepatol. 2011 Sep;55(3):654-‐659.

Saüc S, Bulla M, Nunes P, Orci L, Marchetti A, Antigny F, Bernheim L, Cosson P, Frieden M, Demaurex N. STIM1L traps and gates Orai1 channels without remodeling the cortical ER. J Cell Sci. 2015 Apr 15;128(8):1568-‐79.

Sundivakkam PC, Freichel M, Singh V, Yuan JP, Vogel SM, Flockerzi V, Malik AB, Tiruppathi C. The Ca(2+) sensor stromal interaction molecule 1 (STIM1) is necessary and sufficient for the store-‐operated Ca(2+) entry function of transient receptor potential canonical (TRPC) 1 and 4 channels in endothelial cells. Mol Pharmacol. 2012 Apr;81(4):510-‐26.

Darbellay B, Arnaudeau S, Bader CR, Konig S, Bernheim L. STIM1L is a new actin-‐ binding splice variant involved in fast repetitive Ca^2+^ release. J Cell Biol. 2011 Jul 25;194(2):335-‐46.

Yang L, Calay ES, Fan J, Arduini A, Kunz RC, Gygi SP, Yalcin A, Fu S, Hotamisligil GS. METABOLISM. S-‐Nitrosylation links obesity-‐associated inflammation to endoplasmic reticulum dysfunction. Science. 2015 Jul 31;349(6247):500-‐6.

Widenmaier SB, Snyder NA, Nguyen TB, Arduini A, Lee GY, Arruda AP, Saksi J, Bartelt A, Hotamisligil GS. NRF1 Is an ER Membrane Sensor that Is Central to Cholesterol Homeostasis. Cell. 2017 Nov 16;171(5):1094-‐1109.

[^1]: The Niels Bohr Institute, University of Copenhagen, Copenhagen, Denmark.

[^2]: These authors contributed equally to this work.
